

# HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the  
Ending the HIV Epidemic Initiative:**

**National HIV Surveillance System Data  
Reported Through December 2023**



U.S. DEPARTMENT OF  
HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE  
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for HIV diagnoses reported to CDC through December 2023.

*HIV Surveillance Data Tables* is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

### **Suggested citation**

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2023. *HIV Surveillance Data Tables* 2024;5(1). <https://www.cdc.gov/hiv-data/initiatives/index.html>. Published May 2024. Accessed [date].

**On the Web:** <https://www.cdc.gov/hiv-data/initiatives/index.html>

### **Confidential information, referrals, and educational material on HIV**

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

### **Acknowledgments**

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Juliet Morales, Anna Satcher Johnson, Zanetta Gant Sumner, Ruiguang Song, Baohua Wu, Sue Reynolds, Abigail Derton, Jianmin Li, Xiaohong Hu, Xueyuan Dong, Emily Zhu, Stacy Cohen, and Michael Friend (editing and desktop publishing).

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

<b>Technical Notes</b>	4
<b>References</b>	7
<b>Tables</b>	
1a Estimated HIV incidence among persons aged $\geq 13$ years, by selected characteristics, 2017–2022—United States	8
1b Estimated HIV incidence among persons aged $\geq 13$ years, by area of residence, 2017–2022—United States and Puerto Rico	10
1c Estimated HIV incidence among persons aged $\geq 13$ years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions	16
2a Estimated HIV prevalence among persons aged $\geq 13$ years, by selected characteristics, 2017–2022—United States	28
2b Estimated HIV prevalence among persons aged $\geq 13$ years, by area of residence, 2017–2022—United States and Puerto Rico	34
2c Estimated HIV prevalence among persons aged $\geq 13$ years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions	40
3a Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, 2017–2023—United States	52
3b Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, 2017–2023—United States and 6 territories and freely associated states	53
3c Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, 2017–2023—United States and 6 territories and freely associated states	54
3d Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, 2017–2023—Ending the HIV Epidemic Phase I jurisdictions	55
4a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by selected characteristics, January 2022 through September 2023—48 states and the District of Columbia	57
4b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2022 through September 2023—48 states and the District of Columbia	59
4c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions	60
5a HIV viral suppression during 2022 among persons aged $\geq 13$ years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by selected characteristics—48 states and the District of Columbia	63
5b HIV viral suppression during 2022 among persons aged $\geq 13$ years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by area of residence—48 states and the District of Columbia	64
5c HIV viral suppression during 2022 among persons aged $\geq 13$ years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	65
6 Ending the HIV Epidemic Phase I jurisdictions	67
7 Monitoring Ending the HIV Epidemic indicators by using data from the National HIV Surveillance System (NHSS) and other reporting systems	69

# Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The included tables provide national-, state-, and county-level (EHE Phase I jurisdictions only; see Table 6) data for the 6 core indicators of the EHE initiative, which are the following:

- **New HIV infections:** the estimated number of new HIV infections in a calendar year
- **Knowledge of HIV status:** the estimated percentage of persons with HIV who have received a diagnosis
- **HIV diagnoses:** the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year
- **Linkage to HIV medical care:** the percentage of persons who have received an HIV diagnosis in a calendar year and were linked to HIV medical care within 1 month
- **HIV viral suppression:** the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year
- **Preexposure prophylaxis (PrEP) coverage:** the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year

The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress.

## SURVEILLANCE OF HIV

Data presented were reported (after the removal of names and other directly identifying information) to the CDC through December 31, 2023. Please use caution when interpreting the following:

- Numbers less than 12.
- Data for the year 2023. Data provided using a National HIV Surveillance System (NHSS) dataset produced prior to reaching a 12-month reporting lag are considered preliminary.
- Data on HIV diagnoses. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV.
- Data on deaths. Deaths and prevalence-based data (HIV viral suppression) for the year 2022 are preliminary and based on death data received by CDC as of December 2023. The following jurisdictions had incomplete reporting of deaths for the year 2022 and should be interpreted with caution: Mississippi, South Carolina, and Utah. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see [https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\\_deaths.htm](https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm).
- Data for the year 2020. Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state/local jurisdictions. As the COVID-19 pandemic

lasted beyond 2020, readers should also consider the potential influence of these pandemic effects on U.S. public health systems when interpreting HIV data for 2021–2022.

- HIV incidence and prevalence estimates. The monthly distribution of diagnoses reported to the Centers for Disease Control and Prevention (CDC) during 2020, 2021, and 2022 were adjusted to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. Estimates for years 2020, 2021, and 2022 should be interpreted with caution. See the Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022* at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html> for additional information.

## TABULATION AND PRESENTATION OF DATA

### New HIV Infections (HIV Incidence)

New HIV infections among persons aged  $\geq 13$  years are estimated using the first CD4 test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infections can be found in the report *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html> for additional information.

### Knowledge of HIV Status

The Knowledge of HIV Status indicator is measured as the percentage of persons aged  $\geq 13$  years with diagnosed HIV (Tables 2a–c). For this measure, the numerator (data reported to CDC) is the number of persons aged  $\geq 13$  years living with diagnosed HIV at the end of the year. The denominator, total HIV prevalence, is the estimated number of persons aged  $\geq 13$  years living with HIV (diagnosed or undiagnosed) at the end of the year. Knowledge of status and prevalence data for the year 2022 are preliminary and based on death data reported to CDC as of December 2023. The following areas had incomplete reporting of deaths for the year 2022, and prevalence estimates should be interpreted with caution: Mississippi, South Carolina, and Utah. Estimates for areas without laws requiring reporting of laboratory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Areas with a lapse in reporting during 2022: Mississippi and West Virginia.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV can be found in the report *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html> for additional information.

### HIV Diagnoses

HIV diagnoses are the numbers of persons aged  $\geq 13$  years with HIV diagnosed during 2017–2023 (Tables 3a–d). Data presented were reported (after the removal of names and other directly identifying information) to CDC.

An evaluation of surveillance data (2017–2021 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the report *Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html>.

## Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged  $\geq 13$  years with HIV diagnosed during January 2022 through September 2023 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–c). The numerator is the number of persons aged  $\geq 13$  years with HIV diagnosed during January 2022 through September 2023 and who had  $\geq 1$  CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged  $\geq 13$  years with HIV diagnosed during January 2022 through September 2023. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2022 through September 2023 and was reported to NHSS through December 2023.

Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Data for Mississippi and West Virginia were included in analyses but should also be interpreted with caution due to a lapse in laboratory reporting that occurred during the year 2022.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-outcomes.html>.

## HIV Viral Suppression

Viral suppression at most recent test during 2022 is measured for persons aged  $\geq 13$  years who resided, as of their most recent known address during 2022, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC and who were alive at the end of 2022 (Tables 5a–c). The numerator is the number of persons aged  $\geq 13$  years with HIV diagnosed by the end of 2021 and who had a VL of  $< 200$  copies/mL at the most recent test in 2022. The denominator is the number of persons aged  $\geq 13$  years with HIV diagnosed by the end of 2021 and who were alive at the end of 2022.

Data used to calculate prevalence are based on deaths reported to CDC as of December 2023. The following areas had incomplete reporting of deaths for the year 2022, and viral suppression data should be interpreted with caution: Mississippi, South Carolina, and Utah.

Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Data for Mississippi and West Virginia were included in analyses but should also be interpreted with caution due to a lapse in laboratory reporting that occurred during the year 2022.

More information on calculating viral suppression can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2022*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-outcomes.html>.

## Preexposure Prophylaxis Coverage

PrEP coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the

numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025. Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities.

## REFERENCES

1. HHS. EHE Overview. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated December 2023. Accessed April 16, 2024.

Table 1a. Estimated HIV incidence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States

	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
	2017			2018			2019		
<b>Sex assigned at birth</b>									
Male	29,500	2.1	28,300–30,700	29,500	2.4	28,100–30,900	28,800	2.8	27,200–30,400
Female	6,700	4.3	6,100–7,200	6,600	4.8	6,000–7,200	6,300	5.5	5,600–7,000
<b>Age at infection (yr)</b>									
13–24	9,900	3.6	9,200–10,600	9,200	4.3	8,400–10,000	8,400	5.1	7,600–9,300
25–34	13,400	3.1	12,600–14,200	13,700	3.5	12,700–14,600	13,500	4.1	12,400–14,600
35–44	6,200	4.6	5,700–6,800	6,400	5.2	5,800–7,100	6,600	5.9	5,800–7,300
45–54	4,200	5.7	3,700–4,600	4,200	6.4	3,700–4,700	3,900	7.7	3,300–4,500
55–64	2,100	8.2	1,700–2,400	2,100	9.1	1,700–2,500	2,200	10.1	1,800–2,700
≥65	500	16.8	340–670	540	18.3	350–730	540	20.9	320–760
<b>Race/ethnicity</b>									
American Indian/Alaska Native	200	26.0	100–300	190	29.8	80–300	220	*32.2	80–350
Asian	530	16.6	360–710	500	19.4	310–690	470	22.3	260–670
Black/African American	14,600	2.9	13,800–15,400	14,500	3.3	13,500–15,400	14,100	3.8	13,000–15,100
Hispanic/Latino <sup>a</sup>	10,400	3.8	9,700–11,200	10,600	4.4	9,700–11,500	10,200	5.2	9,100–11,200
Native Hawaiian/other Pacific Islander	...	...	...	...	...	...	...	...	...
White	8,900	3.7	8,200–9,500	8,900	4.1	8,200–9,600	8,700	4.7	7,900–9,500
Multiracial	1,500	10.0	1,200–1,700	1,400	11.3	1,100–1,700	1,400	12.9	1,000–1,700
<b>Transmission category<sup>b</sup></b>									
Male-to-male sexual contact <sup>c</sup>	24,200	2.3	23,100–25,300	23,900	2.7	22,700–25,200	23,300	3.1	21,800–24,700
Injection drug use <sup>d</sup>	2,500	6.6	2,200–2,800	2,700	7.2	2,300–3,100	2,700	8.3	2,300–3,200
Male	1,400	9.7	1,100–1,600	1,500	10.4	1,200–1,800	1,600	11.8	1,200–1,900
Female	1,100	8.6	940–1,300	1,200	9.8	950–1,400	1,200	11.1	920–1,400
Male-to-male sexual contact <sup>c</sup> and injection drug use <sup>d</sup>	1,400	8.4	1,200–1,700	1,500	8.9	1,300–1,800	1,500	10.1	1,200–1,800
Heterosexual contact <sup>e</sup>	8,000	4.5	7,300–8,700	7,900	4.9	7,200–8,700	7,500	5.8	6,700–8,400
Male	2,500	9.4	2,000–2,900	2,500	10.4	2,000–3,000	2,400	11.9	1,900–3,000
Female	5,500	4.9	5,000–6,000	5,400	5.4	4,800–6,000	5,100	6.4	4,500–5,700
<b>Region of residence<sup>f</sup></b>									
Northeast	5,000	5.2	4,400–5,500	4,800	6.0	4,200–5,400	4,700	7.0	4,100–5,400
Midwest	5,000	5.0	4,500–5,500	4,800	5.8	4,300–5,400	4,700	6.7	4,100–5,300
South	18,600	2.6	17,600–19,600	18,600	3.0	17,500–19,700	18,100	3.5	16,800–19,300
West	7,700	4.2	7,000–8,300	7,900	4.7	7,200–8,700	7,700	5.5	6,800–8,500
<b>Total<sup>g</sup></b>	<b>36,200</b>	<b>1.9</b>	<b>34,800–37,500</b>	<b>36,200</b>	<b>2.2</b>	<b>34,600–37,700</b>	<b>35,100</b>	<b>2.5</b>	<b>33,400–36,800</b>



Table 1a. Estimated HIV incidence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)

	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
	2020 (COVID-19 pandemic) <sup>h</sup>			2021 <sup>h</sup>			2022 <sup>h</sup>		
<b>Sex assigned at birth</b>									
Male	28,400	3.5	26,400–30,300	26,500	4.0	24,400–28,600	25,900	4.7	23,500–28,200
Female	5,800	6.9	5,000–6,600	6,200	7.1	5,300–7,000	5,900	8.1	5,000–6,900
<b>Age at infection (yr)</b>									
13–24	7,600	6.6	6,600–8,500	6,800	7.7	5,800–7,800	6,400	9.2	5,200–7,500
25–34	13,700	4.9	12,400–15,000	13,000	5.6	11,600–14,400	12,700	6.6	11,000–14,300
35–44	6,600	7.0	5,700–7,600	6,700	7.7	5,700–7,700	6,700	8.9	5,600–7,900
45–54	3,700	9.4	3,000–4,400	3,600	10.5	2,800–4,300	3,400	12.4	2,600–4,300
55–64	2,100	12.2	1,600–2,600	2,100	13.4	1,600–2,700	2,100	15.7	1,500–2,800
≥65	480	25.9	240–720	540	27.7	250–830	520	*31.5	200–840
<b>Race/ethnicity</b>									
American Indian/Alaska Native	230	*36.3	70–390	180	*46.4	20–340	200	*48.4	10–390
Asian	480	26.4	230–720	430	*31.1	170–690	380	*36.5	110–660
Black/African American	13,600	4.7	12,300–14,800	13,000	5.3	11,700–14,400	11,900	6.3	10,500–13,400
Hispanic/Latino <sup>a</sup>	10,000	6.5	8,700–11,300	9,800	7.2	8,400–11,200	10,500	8.2	8,800–12,100
Native Hawaiian/other Pacific Islander	...	...	...	...	...	...	...	...	...
White	8,600	5.6	7,600–9,500	8,100	6.3	7,100–9,100	7,600	7.5	6,500–8,700
Multiracial	1,200	16.4	830–1,600	1,100	19.2	660–1,500	1,200	20.4	710–1,600
<b>Transmission category<sup>b</sup></b>									
Male-to-male sexual contact <sup>c</sup>	23,200	3.8	21,400–24,900	21,600	4.4	19,700–23,500	21,400	5.2	19,200–23,500
Injection drug use <sup>d</sup>	2,600	10.5	2,100–3,200	2,600	12.1	1,900–3,200	2,300	15.0	1,600–3,000
Male	1,700	14.0	1,200–2,100	1,500	17.1	1,000–2,000	1,300	21.8	730–1,800
Female	970	15.2	680–1,300	1,100	16.5	710–1,400	1,000	19.6	640–1,400
Male-to-male sexual contact <sup>c</sup> and injection drug use <sup>d</sup>	1,400	12.9	1,000–1,700	1,300	14.5	920–1,600	1,100	18.5	670–1,400
Heterosexual contact <sup>e</sup>	6,900	7.1	6,000–7,900	7,200	7.4	6,100–8,200	7,000	8.4	5,900–8,200
Male	2,100	15.4	1,500–2,700	2,100	16.5	1,400–2,800	2,100	18.2	1,400–2,900
Female	4,800	7.7	4,100–5,600	5,100	7.9	4,300–5,900	4,900	9.0	4,000–5,700
<b>Region of residence<sup>f</sup></b>									
Northeast	4,500	8.7	3,700–5,300	4,100	10.0	3,300–4,900	4,400	11.2	3,400–5,300
Midwest	4,800	7.9	4,100–5,600	4,700	8.9	3,900–5,500	4,300	10.8	3,400–5,200
South	17,100	4.4	15,600–18,600	16,700	4.9	15,100–18,300	15,700	5.8	14,000–17,500
West	7,700	6.7	6,700–8,800	7,100	7.7	6,100–8,200	7,400	8.9	6,100–8,600
<b>Total<sup>g</sup></b>	<b>34,200</b>	<b>3.1</b>	<b>32,100–36,300</b>	<b>32,700</b>	<b>3.5</b>	<b>30,400–34,900</b>	<b>31,800</b>	<b>4.1</b>	<b>29,200–34,400</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (\*) and should be used with caution. Estimates with an RSE of >50% are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Hispanic/Latino persons can be of any race.

<sup>b</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of data by transmission category is inaccurate and discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

<sup>c</sup> Includes persons who were assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons who were assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>d</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>e</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>f</sup> Region of residence defined by the U.S. Census. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>.

<sup>g</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

<sup>h</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico**

Area of residence	No.	RSE (%)	95% CI
	2017		
Alabama	640	13.5	470–800
Alaska	...	...	...
Arizona	820	14.2	590–1,000
Arkansas	270	20.8	160–380
California	4,800	5.2	4,300–5,300
Colorado	430	16.6	290–570
Connecticut	230	22.2	130–320
Delaware	120	*34.6	40–200
District of Columbia	220	25.1	110–330
Florida	4,100	5.9	3,600–4,500
Georgia	2,500	7.7	2,100–2,900
Hawaii	80	*38.4	20–150
Idaho <sup>a</sup>	...	...	...
Illinois	1,200	10.5	990–1,500
Indiana	520	15.3	370–680
Iowa	100	*36.9	30–170
Kansas	100	*40.6	20–180
Kentucky	360	19.5	220–490
Louisiana	920	11.7	710–1,100
Maine	...	...	...
Maryland	750	13.8	550–960
Massachusetts	480	15.3	340–630
Michigan	640	13.2	480–810
Minnesota	260	20.7	150–370
Mississippi <sup>a</sup>	440	16.6	290–580
Missouri	530	12.3	400–660
Montana	...	...	...
Nebraska	100	*36.1	30–160
Nevada	490	16.1	330–640
New Hampshire	...	...	...
New Jersey <sup>a</sup>	1,100	12.8	810–1,400
New Mexico	140	26.4	70–220
New York	2,300	7.6	1,900–2,600
North Carolina	1,300	9.2	1,100–1,500
North Dakota	...	...	...
Ohio	950	11.5	740–1,200
Oklahoma	350	18.2	230–480
Oregon	190	27.0	90–290
Pennsylvania	960	12.8	720–1,200
Puerto Rico <sup>a</sup>	410	19.4	250–560
Rhode Island	80	*31.7	30–130
South Carolina	680	14.0	490–870
South Dakota	...	...	...
Tennessee	750	12.3	570–940
Texas	4,400	5.3	4,000–4,900
Utah	140	29.7	60–220
Vermont	...	...	...
Virginia	850	12.8	630–1,100
Washington	500	17.6	330–680
West Virginia <sup>a</sup>	120	*38.0	30–220
Wisconsin	240	21.7	140–340
Wyoming	...	...	...

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	No.	RSE (%)	95% CI
	2018		
Alabama	620	15.6	430–810
Alaska	...	...	...
Arizona	860	16.3	580–1,100
Arkansas	240	26.3	110–360
California	4,800	5.9	4,200–5,300
Colorado	390	20.2	240–550
Connecticut	190	27.9	90–290
Delaware	100	*45.3	10–180
District of Columbia	230	25.5	120–350
Florida	3,900	6.9	3,300–4,400
Georgia	2,400	9.3	2,000–2,900
Hawaii	...	...	...
Idaho <sup>a</sup>	...	...	...
Illinois	1,300	11.9	970–1,600
Indiana	550	16.9	370–730
Iowa	120	*35.8	40–200
Kansas	120	*40.6	20–220
Kentucky	430	19.4	260–590
Louisiana	910	13.1	680–1,100
Maine	...	...	...
Maryland	790	14.8	560–1,000
Massachusetts	560	15.4	390–720
Michigan	610	15.3	430–800
Minnesota	320	21.5	190–460
Mississippi <sup>a</sup>	470	17.9	310–640
Missouri	500	14.7	360–640
Montana	...	...	...
Nebraska	...	...	...
Nevada	560	16.6	380–750
New Hampshire	...	...	...
New Jersey <sup>a</sup>	900	16.2	620–1,200
New Mexico	190	25.5	90–280
New York	2,000	9.3	1,600–2,400
North Carolina	1,300	10.4	1,000–1,600
North Dakota	...	...	...
Ohio	910	13.7	660–1,100
Oklahoma	340	21.1	200–480
Oregon	210	*30.4	80–330
Pennsylvania	1,100	12.5	800–1,300
Puerto Rico <sup>a</sup>	380	21.7	220–540
Rhode Island	60	*41.6	10–120
South Carolina	700	16.0	480–910
South Dakota	...	...	...
Tennessee	780	13.6	570–990
Texas	4,500	6.0	4,000–5,100
Utah	150	*32.5	50–240
Vermont	...	...	...
Virginia	840	14.3	600–1,100
Washington	550	18.8	340–750
West Virginia <sup>a</sup>	180	*36.0	50–310
Wisconsin	200	27.8	90–310
Wyoming	...	...	...

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	No.	RSE (%)	95% CI
	2019		
Alabama	560	18.9	350–770
Alaska	...	...	...
Arizona	790	20.4	470–1,100
Arkansas	310	25.2	160–460
California	4,400	6.9	3,800–5,100
Colorado	450	20.6	270–640
Connecticut	150	*37.0	40–260
Delaware	...	...	...
District of Columbia	200	*31.8	70–320
Florida	3,800	8.1	3,200–4,400
Georgia	2,400	11.2	1,900–2,900
Hawaii	...	...	...
Idaho <sup>a</sup>	...	...	...
Illinois	1,200	14.8	820–1,500
Indiana	500	20.7	300–710
Iowa	140	*36.4	40–240
Kansas	180	*34.7	60–300
Kentucky	350	26.2	170–530
Louisiana	820	16.4	560–1,100
Maine	...	...	...
Maryland	700	17.9	460–950
Massachusetts	460	19.6	280–640
Michigan	570	18.4	360–770
Minnesota	260	27.0	120–400
Mississippi <sup>a</sup>	500	19.6	310–690
Missouri	460	17.2	300–610
Montana	...	...	...
Nebraska	...	...	...
Nevada	570	19.2	360–790
New Hampshire	...	...	...
New Jersey <sup>a</sup>	1,000	16.5	700–1,400
New Mexico	180	29.5	80–290
New York	2,000	10.6	1,600–2,400
North Carolina	1,500	10.9	1,100–1,800
North Dakota	...	...	...
Ohio	880	15.7	610–1,200
Oklahoma	430	20.4	260–600
Oregon	220	*35.0	70–360
Pennsylvania	890	15.1	630–1,200
Puerto Rico <sup>a</sup>	340	26.4	160–510
Rhode Island	70	*44.3	10–130
South Carolina	630	19.3	390–870
South Dakota	...	...	...
Tennessee	830	14.6	590–1,100
Texas	4,500	6.9	3,900–5,200
Utah	150	*37.2	40–260
Vermont	...	...	...
Virginia	770	17.2	510–1,000
Washington	470	24.0	250–690
West Virginia <sup>a</sup>	260	*35.7	80–440
Wisconsin	230	29.6	100–370
Wyoming	...	...	...

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	No.	RSE (%)	95% CI
	2020 (COVID-19 pandemic) <sup>b</sup>		
Alabama	590	21.6	340–840
Alaska	...	...	...
Arizona	780	28.8	340–1,200
Arkansas	290	*30.8	120–470
California	4,400	8.0	3,700–5,100
Colorado	380	27.5	170–580
Connecticut	200	*38.0	50–350
Delaware	120	*49.8	0–230
District of Columbia	150	*45.4	20–280
Florida	3,700	10.2	2,900–4,400
Georgia	2,200	15.2	1,500–2,800
Hawaii	...	...	...
Idaho <sup>a</sup>	...	...	...
Illinois	1,100	18.1	730–1,500
Indiana	630	21.5	370–900
Iowa	120	*47.1	10–230
Kansas	180	*40.0	40–310
Kentucky	380	*30.8	150–610
Louisiana	850	19.3	530–1,200
Maine	...	...	...
Maryland	660	20.9	390–930
Massachusetts	400	23.0	220–590
Michigan	600	20.3	360–840
Minnesota	240	*32.7	90–400
Mississippi <sup>a</sup>	480	23.7	260–700
Missouri	440	21.1	260–630
Montana	...	...	...
Nebraska	...	...	...
Nevada	600	22.4	330–860
New Hampshire	...	...	...
New Jersey <sup>a</sup>	900	23.6	480–1,300
New Mexico	140	*42.1	20–260
New York	1,900	13.4	1,400–2,300
North Carolina	1,300	14.0	920–1,600
North Dakota	...	...	...
Ohio	790	19.6	490–1,100
Oklahoma	430	24.1	230–640
Oregon	250	*41.7	50–450
Pennsylvania	870	18.2	560–1,200
Puerto Rico <sup>a</sup>	280	*36.0	80–470
Rhode Island	...	...	...
South Carolina	690	21.1	410–980
South Dakota	...	...	...
Tennessee	730	18.9	460–990
Texas	4,400	8.8	3,600–5,100
Utah	150	*42.7	20–280
Vermont	...	...	...
Virginia	720	20.3	440–1,000
Washington	430	*30.2	180–690
West Virginia <sup>a</sup>	...	...	...
Wisconsin	350	29.4	150–540
Wyoming	...	...	...

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	No.	RSE (%)	95% CI
	2021 <sup>b</sup>		
Alabama	760	20.3	460–1,100
Alaska	...	...	...
Arizona	800	*30.9	310–1,300
Arkansas	330	29.9	140–530
California	4,100	9.5	3,300–4,800
Colorado	460	26.9	210–700
Connecticut	150	*47.3	10–290
Delaware	...	...	...
District of Columbia	140	*45.6	20–270
Florida	3,600	11.1	2,800–4,400
Georgia	2,000	17.8	1,300–2,700
Hawaii	...	...	...
Idaho <sup>a</sup>	...	...	...
Illinois	1,100	20.7	630–1,500
Indiana	560	24.4	290–820
Iowa	140	*46.1	10–270
Kansas	160	*47.9	10–310
Kentucky	420	*33.0	150–690
Louisiana	800	21.2	470–1,100
Maine	...	...	...
Maryland	630	23.6	340–920
Massachusetts	400	25.9	200–610
Michigan	600	22.3	340–860
Minnesota	210	*38.9	50–370
Mississippi <sup>a</sup>	470	27.0	220–730
Missouri	490	20.6	290–690
Montana	...	...	...
Nebraska	...	...	...
Nevada	510	27.9	230–790
New Hampshire	...	...	...
New Jersey <sup>a</sup>	880	23.3	480–1,300
New Mexico	...	...	...
New York	1,600	15.6	1,100–2,100
North Carolina	1,100	16.2	760–1,500
North Dakota	...	...	...
Ohio	900	22.7	500–1,300
Oklahoma	400	27.6	180–620
Oregon	...	...	...
Pennsylvania	680	22.8	380–990
Puerto Rico <sup>a</sup>	290	*35.9	80–490
Rhode Island	...	...	...
South Carolina	650	27.1	300–990
South Dakota	...	...	...
Tennessee	750	19.4	470–1,000
Texas	4,200	10.0	3,400–5,000
Utah	150	*49.4	0–300
Vermont	...	...	...
Virginia	660	23.0	360–960
Washington	480	*31.3	190–780
West Virginia <sup>a</sup>	...	...	...
Wisconsin	240	*41.4	40–430
Wyoming	...	...	...

**Table 1b. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	No.	RSE (%)	95% CI
	2022 <sup>b</sup>		
Alabama	690	25.5	340–1,000
Alaska	...	...	...
Arizona	710	*38.1	180–1,200
Arkansas	400	*34.7	130–670
California	4,100	10.5	3,300–5,000
Colorado	470	*30.9	190–760
Connecticut	210	*41.5	40–380
Delaware	...	...	...
District of Columbia	140	*47.2	10–270
Florida	3,200	13.1	2,400–4,000
Georgia	2,100	18.8	1,300–2,900
Hawaii	...	...	...
Idaho <sup>a</sup>	...	...	...
Illinois	1,000	23.6	550–1,500
Indiana	510	28.8	220–800
Iowa	...	...	...
Kansas	...	...	...
Kentucky	360	*45.5	40–690
Louisiana	700	26.8	330–1,100
Maine	...	...	...
Maryland	550	*30.1	230–880
Massachusetts	400	29.7	170–630
Michigan	600	27.1	280–920
Minnesota	220	*47.6	10–420
Mississippi <sup>a</sup>	430	*37.4	110–740
Missouri	480	24.5	250–700
Montana	...	...	...
Nebraska	...	...	...
Nevada	480	*34.6	150–800
New Hampshire	...	...	...
New Jersey <sup>a</sup>	790	25.8	390–1,200
New Mexico	...	...	...
New York	1,700	17.1	1,100–2,200
North Carolina	1,000	19.6	640–1,400
North Dakota	...	...	...
Ohio	880	*30.4	350–1,400
Oklahoma	380	*34.0	130–630
Oregon	...	...	...
Pennsylvania	740	23.8	390–1,100
Puerto Rico <sup>a</sup>	230	*50.0	0–450
Rhode Island	...	...	...
South Carolina	690	*30.6	280–1,100
South Dakota	...	...	...
Tennessee	650	24.4	340–970
Texas	4,200	11.4	3,300–5,200
Utah	...	...	...
Vermont	...	...	...
Virginia	620	26.3	300–940
Washington	440	*42.8	70–810
West Virginia <sup>a</sup>	...	...	...
Wisconsin	230	*46.0	20–440
Wyoming	...	...	...

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (\*) and should be used with caution. Estimates with an RSE of >50% are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Areas with a lapse in reporting during 2022: Mississippi and West Virginia.

<sup>b</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	No.	RSE (%)	95% CI
	2017		
<b>Arizona</b>			
Maricopa County	590	16.8	400–790
<b>California</b>			
Alameda County	170	26.9	80–260
Los Angeles County	1,400	9.5	1,200–1,700
Orange County	350	18.6	220–480
Riverside County	310	19.9	190–430
Sacramento County	200	24.6	100–300
San Bernardino County	310	20.1	190–430
San Diego County	480	16.0	330–630
San Francisco County	210	*40.6	40–370
<b>District of Columbia</b>	220	25.1	110–330
<b>Florida</b>			
Broward County	520	16.5	350–690
Duval County	330	20.4	200–470
Hillsborough County	330	20.7	190–460
Miami-Dade County	880	12.6	660–1,100
Orange County	410	18.5	260–560
Palm Beach County	240	23.7	130–360
Pinellas County	200	26.4	100–300
<b>Georgia</b>			
Cobb County	190	27.3	90–290
DeKalb County	320	20.8	190–440
Fulton County	570	15.5	400–740
Gwinnett County	160	28.6	70–260
<b>Illinois</b>			
Cook County	880	12.4	660–1,100
<b>Indiana</b>			
Marion County	240	21.1	140–330
<b>Louisiana</b>			
East Baton Rouge Parish	170	24.1	90–250
Orleans Parish	140	28.1	60–210
<b>Maryland</b>			
Baltimore City	190	27.7	90–300
Montgomery County	90	*40.9	20–160
Prince George's County	200	27.5	90–310
<b>Massachusetts</b>			
Suffolk County	120	26.6	60–180
<b>Michigan</b>			
Wayne County	250	20.6	150–360



**Table 1c. Estimated HIV incidence among persons aged  $\geq 13$  years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2017 (cont)		
<b>Nevada</b>			
Clark County	440	16.2	300–580
<b>New Jersey</b>			
Essex County <sup>a</sup>	290	23.6	150–420
Hudson County <sup>a</sup>	150	*32.9	50–250
<b>New York</b>			
Bronx County	420	17.2	280–560
Kings County	480	15.9	330–630
New York County	330	18.8	210–450
Queens County	340	19.4	210–470
<b>North Carolina</b>			
Mecklenburg County	300	18.6	190–400
<b>Ohio</b>			
Cuyahoga County	120	*31.7	50–200
Franklin County	190	25.7	90–280
Hamilton County	160	27.4	70–250
<b>Pennsylvania</b>			
Philadelphia County	390	17.3	260–520
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	100	*42.4	20–170
<b>Tennessee</b>			
Shelby County	240	20.5	140–340
<b>Texas</b>			
Bexar County	320	19.4	200–440
Dallas County	870	11.9	670–1,100
Harris County	1,200	10.3	920–1,400
Tarrant County	320	20.0	190–440
Travis County	200	24.5	110–300
<b>Washington</b>			
King County	250	25.7	120–370
<b>Total</b>	<b>17,700</b>	<b>2.7</b>	<b>16,800–18,700</b>

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2018		
<b>Arizona</b>			
Maricopa County	560	20.7	330–780
<b>California</b>			
Alameda County	160	*31.4	60–260
Los Angeles County	1,400	10.7	1,100–1,700
Orange County	310	22.3	180–450
Riverside County	320	22.3	180–460
Sacramento County	250	25.0	130–370
San Bernardino County	290	23.2	160–430
San Diego County	460	18.3	300–630
San Francisco County	220	*45.9	20–410
<b>District of Columbia</b>	230	25.5	120–350
<b>Florida</b>			
Broward County	360	22.9	200–520
Duval County	300	24.7	160–450
Hillsborough County	300	24.8	160–450
Miami-Dade County	830	14.9	590–1,100
Orange County	390	22.0	220–550
Palm Beach County	290	25.4	140–430
Pinellas County	190	*31.7	70–300
<b>Georgia</b>			
Cobb County	150	*36.5	40–250
DeKalb County	370	23.1	200–540
Fulton County	590	18.3	380–800
Gwinnett County	140	*37.4	40–240
<b>Illinois</b>			
Cook County	830	14.8	590–1,100
<b>Indiana</b>			
Marion County	230	24.1	120–340
<b>Louisiana</b>			
East Baton Rouge Parish	180	25.9	90–280
Orleans Parish	130	*30.7	50–210
<b>Maryland</b>			
Baltimore City	220	28.1	100–330
Montgomery County	90	*44.9	10–160
Prince George's County	230	27.2	110–350
<b>Massachusetts</b>			
Suffolk County	120	28.3	50–190
<b>Michigan</b>			
Wayne County	260	22.8	140–370

**Table 1c. Estimated HIV incidence among persons aged  $\geq 13$  years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2018 (cont)		
<b>Nevada</b>			
Clark County	490	17.1	320–650
<b>New Jersey</b>			
Essex County <sup>a</sup>	200	*33.9	70–330
Hudson County <sup>a</sup>	150	*38.8	30–260
<b>New York</b>			
Bronx County	380	20.3	230–530
Kings County	480	17.7	320–650
New York County	330	21.4	190–470
Queens County	260	24.2	140–390
<b>North Carolina</b>			
Mecklenburg County	270	22.4	150–390
<b>Ohio</b>			
Cuyahoga County	110	*37.5	30–200
Franklin County	200	28.2	90–310
Hamilton County	150	*31.7	60–250
<b>Pennsylvania</b>			
Philadelphia County	420	18.1	270–560
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	90	*48.2	0–170
<b>Tennessee</b>			
Shelby County	260	21.8	150–370
<b>Texas</b>			
Bexar County	310	22.7	170–440
Dallas County	890	13.7	650–1,100
Harris County	1,100	12.2	830–1,400
Tarrant County	320	22.6	180–460
Travis County	220	27.2	100–330
<b>Washington</b>			
King County	250	27.3	120–380
<b>Total</b>	<b>17,300</b>	<b>3.1</b>	<b>16,200–18,300</b>

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
2019			
<b>Arizona</b>			
Maricopa County	520	25.9	250–780
<b>California</b>			
Alameda County	190	*32.8	70–310
Los Angeles County	1,400	12.3	1,000–1,700
Orange County	280	26.9	130–430
Riverside County	310	25.5	160–470
Sacramento County	200	*32.2	70–320
San Bernardino County	320	25.4	160–470
San Diego County	440	21.6	250–620
San Francisco County	...	...	...
<b>District of Columbia</b>	200	*31.8	70–320
<b>Florida</b>			
Broward County	350	26.3	170–530
Duval County	270	*30.5	110–430
Hillsborough County	290	29.0	130–460
Miami-Dade County	820	17.3	540–1,100
Orange County	480	22.7	260–690
Palm Beach County	270	*30.0	110–430
Pinellas County	200	*35.2	60–330
<b>Georgia</b>			
Cobb County	190	*37.9	50–340
DeKalb County	330	29.1	140–520
Fulton County	500	23.7	270–740
Gwinnett County	190	*38.2	50–340
<b>Illinois</b>			
Cook County	820	17.6	540–1,100
<b>Indiana</b>			
Marion County	230	28.8	100–360
<b>Louisiana</b>			
East Baton Rouge Parish	180	*32.4	60–290
Orleans Parish	110	*41.6	20–200
<b>Maryland</b>			
Baltimore City	140	*41.0	30–250
Montgomery County	...	...	...
Prince George's County	210	*32.9	80–350
<b>Massachusetts</b>			
Suffolk County	110	*31.2	40–180
<b>Michigan</b>			
Wayne County	270	25.4	130–400

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
2019 (cont)			
<b>Nevada</b>			
Clark County	470	20.3	280–660
<b>New Jersey</b>			
Essex County <sup>a</sup>	190	*38.1	50–340
Hudson County <sup>a</sup>	...	...	...
<b>New York</b>			
Bronx County	380	23.0	210–550
Kings County	420	21.6	240–600
New York County	300	25.8	150–450
Queens County	270	27.2	120–410
<b>North Carolina</b>			
Mecklenburg County	330	22.6	180–470
<b>Ohio</b>			
Cuyahoga County	120	*41.6	20–210
Franklin County	210	*30.4	90–340
Hamilton County	140	*37.7	40–240
<b>Pennsylvania</b>			
Philadelphia County	430	20.4	260–600
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	...	...	...
<b>Tennessee</b>			
Shelby County	300	22.3	170–430
<b>Texas</b>			
Bexar County	390	23.2	210–570
Dallas County	690	17.7	450–930
Harris County	1,100	14.0	790–1,400
Tarrant County	430	22.5	240–620
Travis County	160	*36.6	40–270
<b>Washington</b>			
King County	200	*37.4	50–350
<b>Total</b>	<b>16,700</b>	<b>3.7</b>	<b>15,500–17,900</b>

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
2020 (COVID-19 pandemic) <sup>b</sup>			
<b>Arizona</b>			
Maricopa County	510	*38.0	130–900
<b>California</b>			
Alameda County	160	*41.6	30–280
Los Angeles County	1,300	14.4	940–1,700
Orange County	340	28.5	150–530
Riverside County	310	29.8	130–480
Sacramento County	170	*40.0	40–310
San Bernardino County	330	28.9	140–510
San Diego County	390	26.3	190–600
San Francisco County	...	...	...
<b>District of Columbia</b>	150	*45.4	20–280
<b>Florida</b>			
Broward County	350	*32.8	130–580
Duval County	370	*32.3	130–600
Hillsborough County	280	*37.3	70–480
Miami-Dade County	740	22.8	410–1,100
Orange County	420	*30.1	170–680
Palm Beach County	330	*34.0	110–550
Pinellas County	230	*40.6	50–410
<b>Georgia</b>			
Cobb County	...	...	...
DeKalb County	270	*42.0	50–500
Fulton County	530	*30.1	220–840
Gwinnett County	...	...	...
<b>Illinois</b>			
Cook County	790	21.9	450–1,100
<b>Indiana</b>			
Marion County	240	*33.8	80–390
<b>Louisiana</b>			
East Baton Rouge Parish	120	*47.4	10–230
Orleans Parish	...	...	...
<b>Maryland</b>			
Baltimore City	170	*41.0	30–310
Montgomery County	...	...	...
Prince George’s County	170	*41.0	30–310
<b>Massachusetts</b>			
Suffolk County	140	*30.3	60–220
<b>Michigan</b>			
Wayne County	280	28.2	130–440

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
2020 (COVID-19 pandemic) <sup>b</sup> (cont)			
<b>Nevada</b>			
Clark County	520	22.9	290–760
<b>New Jersey</b>			
Essex County <sup>a</sup>	200	*46.1	20–380
Hudson County <sup>a</sup>	...	...	...
<b>New York</b>			
Bronx County	360	28.0	160–550
Kings County	410	26.1	200–620
New York County	250	*33.6	80–410
Queens County	270	*32.5	100–440
<b>North Carolina</b>			
Mecklenburg County	280	29.7	110–440
<b>Ohio</b>			
Cuyahoga County	130	*46.8	10–250
Franklin County	160	*41.6	30–300
Hamilton County	150	*44.0	20–270
<b>Pennsylvania</b>			
Philadelphia County	290	*33.3	100–480
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	...	...	...
<b>Tennessee</b>			
Shelby County	240	29.4	100–390
<b>Texas</b>			
Bexar County	350	*31.3	140–560
Dallas County	740	21.5	430–1,100
Harris County	1,000	18.5	630–1,400
Tarrant County	490	26.4	230–740
Travis County	170	*44.4	20–320
<b>Washington</b>			
King County	220	*41.8	40–400
<b>Total</b>	<b>16,100</b>	<b>4.6</b>	<b>14,700–17,600</b>

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2021 <sup>b</sup>		
<b>Arizona</b>			
Maricopa County	500	*40.8	100–900
<b>California</b>			
Alameda County	150	*48.6	10–290
Los Angeles County	1,100	17.7	720–1,500
Orange County	280	*35.1	90–480
Riverside County	250	*37.2	70–430
Sacramento County	150	*47.9	10–300
San Bernardino County	310	*33.8	100–510
San Diego County	420	28.9	180–650
San Francisco County	...	...	...
<b>District of Columbia</b>	140	*45.6	20–270
<b>Florida</b>			
Broward County	320	*37.6	80–550
Duval County	350	*35.8	100–600
Hillsborough County	...	...	...
Miami-Dade County	750	24.6	390–1,100
Orange County	470	*30.9	190–760
Palm Beach County	220	*45.0	30–420
Pinellas County	...	...	...
<b>Georgia</b>			
Cobb County	...	...	...
DeKalb County	...	...	...
Fulton County	550	*33.9	180–910
Gwinnett County	...	...	...
<b>Illinois</b>			
Cook County	740	25.2	370–1,100
<b>Indiana</b>			
Marion County	220	*36.9	60–380
<b>Louisiana</b>			
East Baton Rouge Parish	...	...	...
Orleans Parish	120	*49.5	0–230
<b>Maryland</b>			
Baltimore City	150	*47.5	10–290
Montgomery County	...	...	...
Prince George's County	200	*41.5	40–360
<b>Massachusetts</b>			
Suffolk County	120	*38.2	30–210
<b>Michigan</b>			
Wayne County	220	*36.2	60–380



**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
2021 <sup>b</sup> (cont)			
<b>Nevada</b>			
Clark County	450	28.5	200–700
<b>New Jersey</b>			
Essex County <sup>a</sup>	190	*47.0	10–360
Hudson County <sup>a</sup>	...	...	...
<b>New York</b>			
Bronx County	380	29.9	160–600
Kings County	350	*30.9	140–570
New York County	230	*38.5	60–400
Queens County	250	*37.2	70–420
<b>North Carolina</b>			
Mecklenburg County	210	*36.4	60–360
<b>Ohio</b>			
Cuyahoga County	...	...	...
Franklin County	...	...	...
Hamilton County	...	...	...
<b>Pennsylvania</b>			
Philadelphia County	290	*35.4	90–490
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	...	...	...
<b>Tennessee</b>			
Shelby County	250	*31.2	100–400
<b>Texas</b>			
Bexar County	310	*36.7	90–530
Dallas County	810	22.8	450–1,200
Harris County	940	21.0	550–1,300
Tarrant County	360	*33.7	120–610
Travis County	170	*49.1	10–340
<b>Washington</b>			
King County	200	*49.4	10–400
<b>Total</b>	<b>14,900</b>	<b>5.3</b>	<b>13,300–16,400</b>

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2022 <sup>b</sup>		
<b>Arizona</b>			
Maricopa County	...	...	...
<b>California</b>			
Alameda County	...	...	...
Los Angeles County	1,200	19.2	740–1,600
Orange County	250	*41.7	50–450
Riverside County	240	*42.1	40–450
Sacramento County	190	*47.7	10–370
San Bernardino County	240	*42.9	40–440
San Diego County	400	*32.9	140–660
San Francisco County	...	...	...
<b>District of Columbia</b>	140	*47.2	10–270
<b>Florida</b>			
Broward County	...	...	...
Duval County	260	*46.8	20–490
Hillsborough County	280	*45.0	30–520
Miami-Dade County	770	27.0	360–1,200
Orange County	400	*37.4	110–690
Palm Beach County	...	...	...
Pinellas County	...	...	...
<b>Georgia</b>			
Cobb County	...	...	...
DeKalb County	390	*45.0	50–730
Fulton County	430	*42.8	70–790
Gwinnett County	...	...	...
<b>Illinois</b>			
Cook County	660	29.7	280–1,000
<b>Indiana</b>			
Marion County	200	*43.3	30–370
<b>Louisiana</b>			
East Baton Rouge Parish	...	...	...
Orleans Parish	...	...	...
<b>Maryland</b>			
Baltimore City	...	...	...
Montgomery County	...	...	...
Prince George's County	200	*49.4	10–390
<b>Massachusetts</b>			
Suffolk County	...	...	...
<b>Michigan</b>			
Wayne County	230	*46.2	20–430

**Table 1c. Estimated HIV incidence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	No.	RSE (%)	95% CI
	2022 <sup>b</sup> (cont)		
<b>Nevada</b>			
Clark County	440	*34.8	140–740
<b>New Jersey</b>			
Essex County <sup>a</sup>	...	...	...
Hudson County <sup>a</sup>	...	...	...
<b>New York</b>			
Bronx County	350	*35.7	100–590
Kings County	370	*34.7	120–620
New York County	210	*46.3	20–390
Queens County	230	*43.5	30–430
<b>North Carolina</b>			
Mecklenburg County	...	...	...
<b>Ohio</b>			
Cuyahoga County	...	...	...
Franklin County	...	...	...
Hamilton County	...	...	...
<b>Pennsylvania</b>			
Philadelphia County	320	*38.0	80–550
<b>Puerto Rico</b>			
San Juan Municipio <sup>a</sup>	...	...	...
<b>Tennessee</b>			
Shelby County	230	*36.7	60–400
<b>Texas</b>			
Bexar County	270	*45.4	30–520
Dallas County	890	25.3	450–1,300
Harris County	810	26.4	390–1,200
Tarrant County	410	*37.0	110–710
Travis County	...	...	...
<b>Washington</b>			
King County	...	...	...
<b>Total</b>	<b>14,000</b>	<b>6.3</b>	<b>12,300–15,800</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only].

*Note.* Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (\*) and should be used with caution. Estimates with an RSE of >50% are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Areas with a lapse in reporting during 2022: Mississippi and West Virginia.

<sup>b</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2017						
<b>Sex assigned at birth</b>							
Male	889,200	0.4	883,100–895,400	752,325	84.6	0.4	84.0–85.2
Female	256,500	0.6	253,400–259,600	227,988	88.9	0.6	87.8–90.0
<b>Age at infection (yr)</b>							
13–24	68,800	1.0	67,500–70,200	27,770	40.3	1.0	39.6–41.2
25–34	206,200	0.5	204,100–208,200	148,225	71.9	0.5	71.2–72.6
35–44	217,000	0.4	215,200–218,900	186,243	85.8	0.4	85.1–86.6
45–54	312,600	0.4	310,400–314,700	290,600	93.0	0.4	92.3–93.6
55–64	249,700	0.5	247,500–251,900	238,553	95.5	0.5	94.7–96.4
≥65	91,400	1.0	89,700–93,200	88,922	97.2	1.0	95.4–99.2
<b>Race/ethnicity</b>							
American Indian/Alaska Native	3,500	5.7	3,100–3,900	2,627	74.8	5.8	67.3–84.2
Asian <sup>b</sup>	16,100	2.4	15,300–16,800	13,326	83.0	2.4	79.3–87.0
Black/African American	457,900	0.5	453,600–462,300	392,165	85.6	0.5	84.8–86.5
Hispanic/Latino <sup>c</sup>	273,800	0.6	270,600–277,100	224,574	82.0	0.6	81.0–83.0
Native Hawaiian/other Pacific Islander	970	10.3	770–1,200	696	72.0	10.8	59.9–90.3
White	327,600	0.6	323,800–331,400	288,708	88.1	0.6	87.1–89.2
Multiracial	65,200	1.1	63,700–66,700	57,581	88.3	1.2	86.4–90.4
<b>Transmission category<sup>d</sup></b>							
Male-to-male sexual contact <sup>e</sup>	657,900	0.4	652,800–663,000	548,254	83.3	0.4	82.7–84.0
Injection drug use <sup>f</sup>	125,800	1.1	123,200–128,500	116,189	92.3	1.1	90.4–94.3
Male	73,100	1.5	71,000–75,200	67,270	92.0	1.5	89.5–94.8
Female	52,700	1.5	51,200–54,300	48,918	92.8	1.5	90.1–95.6
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	64,000	1.3	62,300–65,600	58,355	91.2	1.3	88.9–93.6
Heterosexual contact <sup>g</sup>	294,200	0.6	290,900–297,600	253,936	86.3	0.6	85.3–87.3
Male	92,100	1.1	90,100–94,100	76,372	83.0	1.1	81.2–84.8
Female	202,200	0.7	199,500–204,900	177,565	87.8	0.7	86.7–89.0
<b>Region of residence<sup>h</sup></b>							
Northeast	247,900	0.7	244,600–251,200	225,953	91.2	0.7	90.0–92.4
Midwest	140,500	0.9	138,100–142,900	116,873	83.2	0.9	81.8–84.6
South	527,400	0.4	522,800–532,000	442,895	84.0	0.4	83.3–84.7
West	230,000	0.7	226,900–233,000	194,592	84.6	0.7	83.5–85.8
<b>Total<sup>i</sup></b>	<b>1,145,800</b>	<b>0.3</b>	<b>1,138,900–1,152,600</b>	<b>980,313</b>	<b>85.6</b>	<b>0.3</b>	<b>85.0–86.1</b>

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2018						
<b>Sex assigned at birth</b>							
Male	907,800	0.4	901,500–914,100	771,468	85.0	0.4	84.4–85.6
Female	259,800	0.6	256,600–263,000	231,618	89.2	0.6	88.1–90.3
<b>Age at infection (yr)</b>							
13–24	63,300	1.2	61,900–64,800	26,640	42.1	1.2	41.1–43.1
25–34	213,600	0.5	211,300–215,900	153,098	71.7	0.5	70.9–72.4
35–44	220,200	0.5	218,200–222,100	188,697	85.7	0.5	84.9–86.5
45–54	300,100	0.4	298,000–302,300	278,764	92.9	0.4	92.2–93.6
55–64	266,800	0.4	264,400–269,100	254,947	95.6	0.4	94.8–96.4
≥65	103,600	0.9	101,700–105,400	100,940	97.5	0.9	95.7–99.3
<b>Race/ethnicity</b>							
American Indian/Alaska Native	3,700	5.7	3,200–4,100	2,746	75.1	5.8	67.5–84.6
Asian <sup>b</sup>	16,600	2.4	15,800–17,400	14,181	85.6	2.4	81.7–89.8
Black/African American	466,000	0.5	461,600–470,500	401,158	86.1	0.5	85.3–86.9
Hispanic/Latino <sup>c</sup>	282,600	0.6	279,200–286,000	232,610	82.3	0.6	81.3–83.3
Native Hawaiian/other Pacific Islander	1,000	10.5	800–1,200	737	73.4	10.9	60.9–92.4
White	331,500	0.6	327,600–335,400	292,944	88.4	0.6	87.3–89.4
Multiracial	65,600	1.2	64,100–67,100	58,074	88.6	1.2	86.6–90.6
<b>Transmission category<sup>d</sup></b>							
Male-to-male sexual contact <sup>e</sup>	675,900	0.4	670,600–681,100	566,603	83.8	0.4	83.2–84.5
Injection drug use <sup>f</sup>	125,200	1.1	122,500–127,900	115,357	92.1	1.1	90.2–94.1
Male	72,600	1.5	70,400–74,700	66,578	91.8	1.5	89.1–94.5
Female	52,600	1.5	51,100–54,200	48,778	92.7	1.5	90.0–95.5
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	64,100	1.3	62,400–65,800	58,514	91.3	1.3	89.0–93.7
Heterosexual contact <sup>g</sup>	298,600	0.6	295,200–302,000	259,019	86.7	0.6	85.8–87.8
Male	93,100	1.1	91,000–95,200	77,713	83.5	1.1	81.7–85.4
Female	205,500	0.7	202,800–208,300	181,306	88.2	0.7	87.1–89.4
<b>Region of residence<sup>h</sup></b>							
Northeast	249,200	0.7	245,800–252,500	227,985	91.5	0.7	90.3–92.7
Midwest	143,400	0.9	141,000–145,900	119,895	83.6	0.9	82.2–85.0
South	539,300	0.4	534,500–544,000	455,228	84.4	0.4	83.7–85.2
West	235,700	0.7	232,500–238,800	199,978	84.9	0.7	83.7–86.0
<b>Total<sup>i</sup></b>	<b>1,167,500</b>	<b>0.3</b>	<b>1,160,500–1,174,600</b>	<b>1,003,086</b>	<b>85.9</b>	<b>0.3</b>	<b>85.4–86.4</b>

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2019						
<b>Sex assigned at birth</b>							
Male	925,500	0.4	919,000–932,100	789,911	85.3	0.4	84.7–86.0
Female	262,800	0.6	259,500–266,100	235,215	89.5	0.6	88.4–90.6
<b>Age at infection (yr)</b>							
13–24	57,900	1.4	56,300–59,400	25,982	44.9	1.4	43.7–46.1
25–34	219,100	0.6	216,600–221,600	156,565	71.5	0.6	70.6–72.3
35–44	224,900	0.5	222,700–227,000	192,065	85.4	0.5	84.6–86.2
45–54	286,600	0.4	284,500–288,800	265,833	92.7	0.4	92.0–93.5
55–64	282,400	0.4	280,000–284,800	270,052	95.6	0.4	94.8–96.4
≥65	117,400	0.9	115,400–119,400	114,629	97.6	0.9	96.0–99.3
<b>Race/ethnicity</b>							
American Indian/Alaska Native	3,800	5.8	3,400–4,300	2,870	75.2	5.9	67.5–84.8
Asian <sup>b</sup>	17,100	2.4	16,300–17,900	14,905	87.4	2.4	83.4–91.7
Black/African American	473,800	0.5	469,200–478,400	409,953	86.5	0.5	85.7–87.4
Hispanic/Latino <sup>c</sup>	290,900	0.6	287,400–294,500	240,725	82.7	0.6	81.7–83.8
Native Hawaiian/other Pacific Islander	1,000	10.6	830–1,300	781	74.8	11.1	61.9–94.5
White	335,100	0.6	331,200–339,100	296,737	88.5	0.6	87.5–89.6
Multiracial	66,000	1.2	64,400–67,500	58,523	88.7	1.2	86.7–90.9
<b>Transmission category<sup>d</sup></b>							
Male-to-male sexual contact <sup>e</sup>	693,000	0.4	687,500–698,500	584,334	84.3	0.4	83.7–85.0
Injection drug use <sup>f</sup>	124,700	1.1	122,000–127,400	114,649	92.0	1.1	90.0–94.0
Male	72,100	1.5	70,000–74,300	65,959	91.4	1.5	88.8–94.3
Female	52,500	1.6	50,900–54,100	48,690	92.7	1.6	89.9–95.6
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	64,300	1.3	62,600–66,000	58,752	91.4	1.4	89.1–93.9
Heterosexual contact <sup>g</sup>	302,600	0.6	299,100–306,200	263,773	87.2	0.6	86.2–88.2
Male	94,000	1.2	91,900–96,200	78,811	83.8	1.2	82.0–85.8
Female	208,600	0.7	205,800–211,400	184,962	88.7	0.7	87.5–89.9
<b>Region of residence<sup>h</sup></b>							
Northeast	250,000	0.7	246,600–253,500	229,466	91.8	0.7	90.5–93.0
Midwest	146,000	0.9	143,500–148,600	122,601	83.9	0.9	82.5–85.4
South	551,100	0.5	546,200–556,100	467,870	84.9	0.5	84.1–85.7
West	241,100	0.7	237,800–244,400	205,189	85.1	0.7	84.0–86.3
<b>Total<sup>i</sup></b>	<b>1,188,300</b>	<b>0.3</b>	<b>1,181,000–1,195,600</b>	<b>1,025,126</b>	<b>86.3</b>	<b>0.3</b>	<b>85.7–86.8</b>

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2020 (COVID-19 pandemic) <sup>j</sup>						
<b>Sex assigned at birth</b>							
Male	936,300	0.4	929,500–943,200	801,450	85.6	0.4	85.0–86.2
Female	263,400	0.7	260,000–266,800	236,372	89.7	0.7	88.6–90.9
<b>Age at infection (yr)</b>							
13–24	51,400	1.7	49,700–53,200	24,111	46.9	1.7	45.4–48.5
25–34	220,100	0.7	217,300–223,000	156,472	71.1	0.7	70.2–72.0
35–44	230,200	0.5	227,900–232,600	195,467	84.9	0.5	84.0–85.8
45–54	273,100	0.4	270,800–275,300	252,816	92.6	0.4	91.8–93.4
55–64	293,600	0.4	291,100–296,000	280,753	95.6	0.4	94.8–96.4
≥65	131,300	0.8	129,100–133,400	128,203	97.7	0.8	96.1–99.3
<b>Race/ethnicity</b>							
American Indian/Alaska Native	3,900	6.0	3,500–4,400	2,966	75.3	6.1	67.3–85.4
Asian <sup>b</sup>	17,400	2.5	16,600–18,300	15,482	88.9	2.5	84.8–93.5
Black/African American	477,500	0.5	472,700–482,200	414,604	86.8	0.5	86.0–87.7
Hispanic/Latino <sup>c</sup>	296,600	0.7	292,800–300,400	246,133	83.0	0.7	81.9–84.0
Native Hawaiian/other Pacific Islander	1,100	11.1	850–1,300	829	76.4	11.6	62.8–97.6
White	336,800	0.6	332,700–340,900	298,769	88.7	0.6	87.6–89.8
Multiracial	65,700	1.2	64,100–67,300	58,408	88.9	1.2	86.8–91.1
<b>Transmission category<sup>d</sup></b>							
Male-to-male sexual contact <sup>e</sup>	705,300	0.4	699,500–711,000	597,308	84.7	0.4	84.0–85.4
Injection drug use <sup>f</sup>	123,100	1.1	120,400–125,900	112,914	91.7	1.1	89.7–93.8
Male	71,300	1.6	69,000–73,500	64,806	90.9	1.6	88.2–93.9
Female	51,900	1.6	50,200–53,500	48,108	92.7	1.6	89.9–95.7
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	63,800	1.4	62,100–65,600	58,333	91.4	1.4	89.0–94.0
Heterosexual contact <sup>g</sup>	303,800	0.6	300,100–307,500	265,670	87.5	0.6	86.4–88.5
Male	93,900	1.2	91,700–96,200	78,977	84.1	1.2	82.1–86.2
Female	209,900	0.7	207,000–212,800	186,693	89.0	0.7	87.7–90.2
<b>Region of residence<sup>h</sup></b>							
Northeast	249,100	0.7	245,600–252,700	229,004	91.9	0.7	90.6–93.2
Midwest	148,000	0.9	145,300–150,600	124,495	84.1	0.9	82.7–85.7
South	558,100	0.5	553,000–563,300	475,892	85.3	0.5	84.5–86.1
West	244,500	0.7	241,000–247,900	208,431	85.3	0.7	84.1–86.5
<b>Total<sup>i</sup></b>	<b>1,199,700</b>	<b>0.3</b>	<b>1,192,100–1,207,300</b>	<b>1,037,822</b>	<b>86.5</b>	<b>0.3</b>	<b>86.0–87.1</b>

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)

	Persons living with diagnosed or undiagnosed HIV infection				Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI	
	2021 <sup>j</sup>							
<b>Sex assigned at birth</b>								
Male	950,500	0.4	943,300–957,600	817,378	86.0	0.4	85.4–86.7	
Female	265,500	0.7	262,000–269,000	238,649	89.9	0.7	88.7–91.1	
<b>Age at infection (yr)</b>								
13–24	46,600	2.0	44,800–48,500	23,814	51.1	2.0	49.1–53.2	
25–34	220,700	0.7	217,500–223,800	157,041	71.2	0.7	70.2–72.2	
35–44	238,300	0.6	235,600–240,900	201,532	84.6	0.6	83.7–85.5	
45–54	262,300	0.5	260,000–264,600	242,192	92.3	0.5	91.5–93.2	
55–64	301,300	0.4	298,800–303,900	288,101	95.6	0.4	94.8–96.4	
≥65	146,700	0.8	144,400–149,000	143,347	97.7	0.8	96.2–99.2	
<b>Race/ethnicity</b>								
American Indian/Alaska Native	4,000	6.2	3,600–4,500	3,099	76.6	6.3	68.3–87.3	
Asian <sup>b</sup>	17,800	2.5	17,000–18,700	16,196	90.8	2.5	86.5–95.5	
Black/African American	482,900	0.5	477,900–487,900	420,925	87.2	0.5	86.3–88.1	
Hispanic/Latino <sup>c</sup>	304,800	0.7	300,800–308,900	254,365	83.4	0.7	82.3–84.6	
Native Hawaiian/other Pacific Islander	1,100	11.5	890–1,400	892	77.8	12.0	63.5–100	
White	339,200	0.6	334,900–343,400	301,724	89.0	0.6	87.9–90.1	
Multiracial	65,400	1.3	63,700–67,000	58,198	89.0	1.3	86.8–91.3	
<b>Transmission category<sup>d</sup></b>								
Male-to-male sexual contact <sup>e</sup>	720,300	0.4	714,200–726,400	613,879	85.2	0.4	84.5–86.0	
Injection drug use <sup>f</sup>	122,000	1.2	119,200–124,800	111,686	91.5	1.2	89.5–93.7	
Male	70,500	1.6	68,200–72,800	63,947	90.7	1.6	87.9–93.7	
Female	51,500	1.6	49,800–53,200	47,739	92.7	1.7	89.8–95.8	
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	63,400	1.4	61,600–65,200	58,038	91.5	1.4	89.0–94.2	
Heterosexual contact <sup>g</sup>	306,400	0.6	302,600–310,300	268,819	87.7	0.6	86.6–88.8	
Male	94,100	1.3	91,800–96,500	79,505	84.5	1.3	82.4–86.6	
Female	212,300	0.7	209,300–215,300	189,314	89.2	0.7	87.9–90.5	
<b>Region of residence<sup>h</sup></b>								
Northeast	249,100	0.7	245,500–252,700	229,628	92.2	0.7	90.9–93.5	
Midwest	150,400	0.9	147,600–153,200	126,914	84.4	0.9	82.8–86.0	
South	567,800	0.5	562,400–573,200	486,944	85.8	0.5	84.9–86.6	
West	248,600	0.7	245,000–252,200	212,541	85.5	0.7	84.3–86.8	
<b>Total<sup>i</sup></b>	<b>1,215,900</b>	<b>0.3</b>	<b>1,208,000–1,223,900</b>	<b>1,056,027</b>	<b>86.8</b>	<b>0.3</b>	<b>86.3–87.4</b>	



**Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017–2022—United States (cont)**

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2022 <sup>j</sup>						
<b>Sex assigned at birth</b>							
Male	969,200	0.4	961,700–976,800	837,568	86.4	0.4	85.7–87.1
Female	268,800	0.7	265,200–272,400	242,183	90.1	0.7	88.9–91.3
<b>Age at infection (yr)</b>							
13–24	42,200	2.4	40,200–44,200	23,762	56.3	2.4	53.7–59.1
25–34	221,600	0.8	218,100–225,200	158,620	71.6	0.8	70.4–72.7
35–44	247,900	0.6	245,000–250,900	208,870	84.3	0.6	83.3–85.3
45–54	255,900	0.5	253,400–258,400	235,527	92.0	0.5	91.2–92.9
55–64	306,400	0.4	303,800–309,100	292,799	95.6	0.4	94.7–96.4
≥65	163,900	0.8	161,500–166,400	160,173	97.7	0.8	96.3–99.2
<b>Race/ethnicity</b>							
American Indian/Alaska Native	4,200	6.4	3,700–4,700	3,240	77.3	6.6	68.6–88.4
Asian <sup>b</sup>	18,400	2.6	17,500–19,300	17,065	92.8	2.6	88.3–97.7
Black/African American	489,200	0.5	484,000–494,400	428,320	87.6	0.5	86.6–88.5
Hispanic/Latino <sup>c</sup>	316,900	0.7	312,500–321,300	266,317	84.0	0.7	82.9–85.2
Native Hawaiian/other Pacific Islander	1,200	11.8	970–1,500	969	80.4	11.0	65.2–100
White	342,200	0.7	337,800–346,600	305,311	89.2	0.7	88.1–90.4
Multiracial	65,300	1.3	63,600–67,000	57,900	88.7	1.3	86.4–91.1
<b>Transmission category<sup>d</sup></b>							
Male-to-male sexual contact <sup>e</sup>	739,200	0.4	732,700–745,600	633,765	85.7	0.4	85.0–86.5
Injection drug use <sup>f</sup>	121,200	1.2	118,300–124,100	110,948	91.5	1.2	89.4–93.8
Male	69,900	1.7	67,600–72,300	63,409	90.7	1.7	87.7–93.8
Female	51,300	1.7	49,600–53,000	47,539	92.7	1.7	89.7–95.9
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	63,000	1.5	61,100–64,800	57,732	91.7	1.5	89.1–94.4
Heterosexual contact <sup>g</sup>	310,900	0.7	306,900–314,900	273,627	88.0	0.7	86.9–89.2
Male	95,100	1.3	92,600–97,600	80,635	84.8	1.3	82.6–87.1
Female	215,800	0.7	212,600–218,900	192,992	89.4	0.7	88.1–90.8
<b>Region of residence<sup>h</sup></b>							
Northeast	251,300	0.8	247,600–255,100	231,940	92.3	0.8	90.9–93.7
Midwest	153,300	1.0	150,400–156,300	129,884	84.7	1.0	83.1–86.4
South	579,900	0.5	574,300–585,600	500,939	86.4	0.5	85.5–87.2
West	253,400	0.8	249,600–257,300	216,988	85.6	0.8	84.3–86.9
<b>Total<sup>i</sup></b>	<b>1,238,000</b>	<b>0.3</b>	<b>1,229,600–1,246,400</b>	<b>1,079,751</b>	<b>87.2</b>	<b>0.3</b>	<b>86.6–87.8</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2022 are preliminary and based on deaths reported to CDC through December 2023. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

<sup>a</sup> Reported to the National HIV Surveillance System.

<sup>b</sup> Includes Asian/Pacific Islander legacy cases.

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of data by transmission category is inaccurate and discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

<sup>e</sup> Includes persons who were assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons who were assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>f</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>g</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>h</sup> Region of residence defined by the U.S. Census. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>.

<sup>i</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

<sup>j</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	2017						
Alabama	15,800	2.6	15,000–16,600	12,862	81.3	2.6	77.4–85.6
Alaska	870	11.0	700–1,100	703	81.0	10.5	66.6–100
Arizona	19,100	2.3	18,300–20,000	15,558	81.3	2.3	77.8–85.1
Arkansas	6,700	3.8	6,200–7,200	5,432	80.6	3.8	75.1–87.1
California	147,600	0.9	145,200–150,100	126,774	85.9	0.9	84.4–87.3
Colorado	13,900	2.6	13,200–14,600	11,932	86.0	2.6	81.9–90.5
Connecticut	11,100	3.1	10,400–11,800	10,116	90.9	3.2	85.6–96.9
Delaware	3,800	5.3	3,400–4,100	3,214	85.5	5.4	77.4–95.5
District of Columbia	15,000	2.7	14,200–15,800	14,000	93.3	2.7	88.5–98.5
Florida	125,400	0.9	123,100–127,700	107,561	85.8	0.9	84.2–87.4
Georgia	63,700	1.2	62,200–65,200	52,058	81.7	1.2	79.8–83.7
Hawaii	2,700	6.5	2,400–3,000	2,367	88.6	6.2	78.6–100
Idaho <sup>b</sup>	1,500	11.3	1,200–1,800	1,099	73.5	11.9	60.1–94.5
Illinois	40,100	1.7	38,800–41,400	34,292	85.5	1.7	82.8–88.3
Indiana	13,200	2.7	12,500–13,900	10,854	82.5	2.7	78.3–87.2
Iowa	3,100	5.1	2,800–3,400	2,630	84.0	5.2	76.3–93.4
Kansas	3,700	5.3	3,300–4,000	2,965	80.9	5.4	73.2–90.3
Kentucky	8,500	3.3	7,900–9,000	6,846	80.6	3.3	75.7–86.2
Louisiana	24,000	2.2	23,000–25,000	19,947	83.0	2.2	79.7–86.7
Maine	1,800	7.7	1,500–2,000	1,541	86.8	7.2	75.4–100
Maryland	36,300	1.7	35,000–37,500	32,068	88.5	1.7	85.6–91.6
Massachusetts	22,100	2.1	21,200–23,000	19,919	90.2	2.1	86.6–94.2
Michigan	18,300	2.5	17,400–19,200	15,429	84.5	2.5	80.6–88.8
Minnesota	9,300	3.1	8,800–9,900	8,124	87.0	3.1	82.1–92.6
Mississippi <sup>b,c</sup>	11,000	3.1	10,300–11,600	9,037	82.5	3.2	77.7–88.0
Missouri	13,900	2.7	13,100–14,600	12,089	87.1	2.7	82.8–92.0
Montana	690	10.4	610–830	606	87.8	7.8	73.0–100
Nebraska	2,500	6.0	2,200–2,800	2,076	83.1	6.1	74.3–94.3
Nevada	11,600	2.8	11,000–12,200	9,384	81.0	2.8	76.9–85.7
New Hampshire	1,300	8.7	1,200–1,500	1,156	88.1	7.1	75.3–100
New Jersey <sup>b</sup>	38,400	1.9	36,900–39,900	33,504	87.3	1.9	84.1–90.7
New Mexico	3,900	4.7	3,600–4,300	3,376	86.2	4.7	79.0–94.8
New York	132,900	0.9	130,400–135,300	122,075	91.9	0.9	90.3–93.6
North Carolina	35,800	1.6	34,600–36,900	30,303	84.7	1.6	82.1–87.5
North Dakota	610	12.7	460–770	402	65.5	13.6	52.4–87.3
Ohio	25,900	2.0	24,900–26,900	21,426	82.7	2.0	79.7–86.0
Oklahoma	7,400	3.7	6,800–7,900	5,908	80.0	3.7	74.6–86.3
Oregon	7,800	3.4	7,200–8,300	6,805	87.7	3.4	82.2–93.9
Pennsylvania	38,700	1.7	37,400–39,900	34,473	89.2	1.7	86.4–92.2
Puerto Rico <sup>b</sup>	17,300	3.1	16,200–18,300	15,405	89.1	3.1	84.0–94.9
Rhode Island	2,800	5.8	2,500–3,100	2,500	89.9	5.5	80.8–100
South Carolina <sup>c</sup>	19,700	2.3	18,800–20,600	16,153	82.1	2.3	78.5–86.0
South Dakota	700	12.0	560–860	561	80.6	11.0	65.2–100
Tennessee	19,900	2.3	19,000–20,700	16,555	83.4	2.3	79.9–87.3
Texas	107,700	1.0	105,600–109,700	87,277	81.1	1.0	79.5–82.6
Utah <sup>c</sup>	3,400	5.3	3,000–3,700	2,724	81.0	5.4	73.4–90.4
Vermont	730	10.2	670–870	669	92.2	6.4	76.9–100
Virginia	25,800	2.0	24,800–26,900	21,930	84.9	2.0	81.6–88.4
Washington	15,100	2.6	14,300–15,900	12,944	85.7	2.6	81.6–90.3
West Virginia <sup>b</sup>	2,300	7.0	2,000–2,600	1,744	76.9	7.2	67.6–89.2
Wisconsin	7,000	3.7	6,500–7,600	6,025	85.5	3.7	79.7–92.1
Wyoming	380	15.3	320–490	320	85.1	10.4	65.4–100

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2018</b>						
Alabama	16,200	2.6	15,400–17,100	13,276	81.7	2.6	77.8–86.1
Alaska	870	11.5	690–1,100	691	79.8	11.2	65.1–100
Arizona	19,900	2.3	19,000–20,800	16,188	81.4	2.3	77.9–85.3
Arkansas	6,800	3.8	6,300–7,400	5,589	81.6	3.9	75.9–88.3
California	150,400	0.9	147,800–152,900	129,525	86.1	0.9	84.7–87.6
Colorado	14,300	2.6	13,600–15,000	12,382	86.4	2.6	82.3–91.0
Connecticut	11,200	3.2	10,500–11,900	10,251	91.6	3.2	86.2–97.6
Delaware	3,800	5.4	3,400–4,200	3,238	85.6	5.5	77.3–95.8
District of Columbia	14,800	2.8	14,000–15,700	13,877	93.5	2.8	88.6–98.9
Florida	127,200	1.0	124,800–129,600	109,671	86.2	1.0	84.6–87.9
Georgia	65,700	1.2	64,100–67,300	54,098	82.3	1.2	80.4–84.4
Hawaii	2,600	6.8	2,300–3,000	2,318	89.0	6.2	78.5–100
Idaho <sup>b</sup>	1,500	11.6	1,200–1,900	1,146	74.2	12.3	60.4–96.1
Illinois	40,800	1.7	39,500–42,100	35,076	86.0	1.7	83.2–88.9
Indiana	13,500	2.7	12,800–14,300	11,193	82.7	2.8	78.5–87.5
Iowa	3,200	5.1	2,900–3,600	2,742	84.5	5.2	76.7–93.9
Kansas	3,700	5.5	3,300–4,100	3,033	81.9	5.5	74.0–91.7
Kentucky	8,800	3.3	8,200–9,400	7,099	80.7	3.4	75.8–86.4
Louisiana	24,400	2.2	23,400–25,500	20,411	83.5	2.2	80.1–87.2
Maine	1,800	7.7	1,600–2,100	1,588	87.3	7.1	75.8–100
Maryland	36,600	1.8	35,300–37,800	32,574	89.1	1.8	86.1–92.3
Massachusetts	22,300	2.1	21,400–23,200	20,222	90.7	2.2	87.0–94.7
Michigan	18,500	2.5	17,600–19,400	15,769	85.2	2.5	81.3–89.6
Minnesota	9,600	3.1	9,100–10,200	8,400	87.1	3.1	82.1–92.6
Mississippi <sup>b,c</sup>	11,100	3.2	10,400–11,800	9,206	82.8	3.2	77.9–88.4
Missouri	14,200	2.7	13,500–15,000	12,385	87.1	2.7	82.8–91.9
Montana	700	10.4	630–850	629	89.3	7.4	74.1–100
Nebraska	2,500	6.2	2,200–2,800	2,113	84.2	6.3	75.1–95.7
Nevada	12,200	2.7	11,600–12,900	9,957	81.5	2.8	77.3–86.1
New Hampshire	1,400	8.5	1,200–1,600	1,221	88.8	6.9	76.1–100
New Jersey <sup>b</sup>	38,400	2.0	36,900–39,900	33,616	87.5	2.0	84.3–91.1
New Mexico	4,100	4.6	3,800–4,500	3,568	86.2	4.6	79.1–94.6
New York	133,100	0.9	130,600–135,500	122,753	92.3	0.9	90.6–94.0
North Carolina	36,800	1.6	35,600–38,000	31,219	84.9	1.6	82.2–87.6
North Dakota	670	12.8	500–840	440	65.5	13.7	52.3–87.4
Ohio	26,400	2.0	25,400–27,400	21,992	83.3	2.0	80.2–86.7
Oklahoma	7,600	3.7	7,000–8,200	6,069	79.8	3.8	74.3–86.1
Oregon	7,900	3.4	7,400–8,500	6,981	88.2	3.5	82.6–94.5
Pennsylvania	39,300	1.7	38,000–40,600	35,097	89.3	1.7	86.4–92.3
Puerto Rico <sup>b</sup>	17,100	3.2	16,000–18,100	15,239	89.3	3.2	84.1–95.3
Rhode Island	2,800	5.8	2,600–3,100	2,550	90.5	5.3	81.2–100
South Carolina <sup>c</sup>	20,100	2.3	19,200–21,000	16,614	82.6	2.3	79.0–86.6
South Dakota	730	11.8	600–910	597	81.3	10.7	66.0–100
Tennessee	20,500	2.2	19,600–21,400	17,157	83.7	2.3	80.2–87.6
Texas	111,300	1.0	109,200–113,400	90,765	81.6	1.0	80.0–83.1
Utah <sup>c</sup>	3,600	5.2	3,200–3,900	2,909	81.4	5.2	73.9–90.6
Vermont	730	10.2	690–880	687	93.8	6.0	78.1–100
Virginia	26,400	2.0	25,300–27,500	22,520	85.3	2.0	82.0–88.9
Washington	15,500	2.6	14,800–16,300	13,344	85.8	2.6	81.7–90.4
West Virginia <sup>b</sup>	2,500	7.1	2,100–2,800	1,845	75.1	7.2	65.9–87.1
Wisconsin	7,200	3.7	6,700–7,700	6,155	85.8	3.7	80.0–92.5
Wyoming	400	15.1	340–510	340	86.0	10.0	66.4–100

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2019</b>						
Alabama	16,600	2.6	15,700–17,400	13,658	82.5	2.6	78.4–86.9
Alaska	900	11.7	710–1,100	709	78.9	11.6	64.1–100
Arizona	20,700	2.4	19,700–21,600	16,908	81.9	2.4	78.2–85.8
Arkansas	7,100	3.9	6,500–7,600	5,794	81.9	3.9	76.1–88.7
California	152,800	0.9	150,200–155,400	132,054	86.4	0.9	85.0–87.9
Colorado	14,700	2.6	13,900–15,400	12,739	86.8	2.6	82.6–91.4
Connecticut	11,200	3.2	10,500–11,900	10,349	92.1	3.2	86.7–98.3
Delaware	3,900	5.5	3,400–4,300	3,321	86.0	5.5	77.7–96.4
District of Columbia	14,800	2.9	13,900–15,600	13,846	93.8	2.9	88.9–99.4
Florida	129,200	1.0	126,700–131,600	111,913	86.6	1.0	85.0–88.3
Georgia	67,600	1.3	65,900–69,300	55,986	82.9	1.3	80.8–85.0
Hawaii	2,600	6.9	2,300–3,000	2,333	89.4	6.1	78.8–100
Idaho <sup>b</sup>	1,700	11.9	1,300–2,000	1,218	73.3	12.6	59.5–95.6
Illinois	40,800	1.7	39,400–42,200	35,212	86.3	1.7	83.5–89.3
Indiana	13,800	2.8	13,000–14,500	11,416	82.9	2.8	78.5–87.7
Iowa	3,400	5.2	3,000–3,700	2,826	83.9	5.2	76.2–93.4
Kansas	3,800	5.6	3,400–4,200	3,096	81.3	5.6	73.3–91.2
Kentucky	9,100	3.4	8,500–9,700	7,394	81.1	3.4	76.1–86.9
Louisiana	24,900	2.2	23,800–25,900	20,880	84.0	2.2	80.5–87.8
Maine	1,800	7.9	1,600–2,100	1,623	88.4	6.8	76.5–100
Maryland	36,500	1.8	35,300–37,800	32,767	89.7	1.8	86.6–92.9
Massachusetts	22,500	2.2	21,500–23,400	20,494	91.1	2.2	87.4–95.2
Michigan	19,000	2.5	18,000–19,900	16,353	86.2	2.5	82.1–90.6
Minnesota	9,900	3.1	9,300–10,500	8,654	87.5	3.1	82.5–93.1
Mississippi <sup>b,c</sup>	11,400	3.2	10,700–12,100	9,475	83.0	3.3	78.0–88.6
Missouri	14,400	2.7	13,600–15,200	12,601	87.5	2.7	83.1–92.4
Montana	720	10.6	650–870	650	90.7	7.0	75.1–100
Nebraska	2,600	6.3	2,300–2,900	2,170	84.5	6.4	75.2–96.3
Nevada	12,800	2.8	12,100–13,500	10,517	82.0	2.8	77.8–86.7
New Hampshire	1,400	8.3	1,300–1,700	1,274	89.2	6.7	76.6–100
New Jersey <sup>b</sup>	38,700	2.0	37,200–40,300	33,996	87.7	2.0	84.4–91.4
New Mexico	4,300	4.6	3,900–4,700	3,738	86.6	4.6	79.5–95.1
New York	132,700	1.0	130,200–135,100	122,774	92.5	1.0	90.8–94.3
North Carolina	38,100	1.6	36,900–39,400	32,473	85.1	1.6	82.5–87.9
North Dakota	720	13.1	530–900	482	67.1	14.0	53.4–90.4
Ohio	27,100	2.0	26,000–28,200	22,801	84.1	2.0	80.9–87.5
Oklahoma	7,900	3.8	7,300–8,500	6,295	79.5	3.8	74.1–85.9
Oregon	8,100	3.5	7,600–8,700	7,182	88.3	3.5	82.6–94.7
Pennsylvania	39,800	1.7	38,500–41,100	35,652	89.6	1.7	86.8–92.7
Puerto Rico <sup>b</sup>	17,100	3.2	16,000–18,200	15,321	89.7	3.2	84.3–95.7
Rhode Island	2,900	5.8	2,600–3,200	2,609	90.7	5.2	81.4–100
South Carolina <sup>c</sup>	20,600	2.4	19,600–21,500	17,166	83.5	2.4	79.8–87.5
South Dakota	760	11.8	630–940	633	82.9	10.1	67.3–100
Tennessee	21,000	2.3	20,100–22,000	17,626	83.9	2.3	80.3–87.8
Texas	114,800	1.0	112,600–117,000	94,148	82.0	1.0	80.4–83.6
Utah <sup>c</sup>	3,700	5.2	3,300–4,100	3,053	81.9	5.3	74.3–91.2
Vermont	740	10.3	700–890	695	94.1	5.9	78.3–100
Virginia	27,000	2.1	25,900–28,100	23,174	85.9	2.1	82.5–89.5
Washington	15,900	2.6	15,100–16,800	13,750	86.2	2.6	82.0–90.9
West Virginia <sup>b</sup>	2,700	7.4	2,300–3,100	1,954	73.0	7.6	63.7–85.5
Wisconsin	7,400	3.7	6,900–7,900	6,357	85.9	3.7	80.1–92.7
Wyoming	390	15.8	340–510	338	87.1	9.8	66.4–100

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2020 (COVID-19 pandemic)<sup>d</sup></b>						
Alabama	16,700	2.7	15,900–17,600	13,911	83.1	2.7	78.9–87.7
Alaska	910	12.2	720–1,100	719	79.4	11.6	64.0–100
Arizona	21,200	2.5	20,100–22,200	17,399	82.1	2.6	78.2–86.5
Arkansas	7,200	4.1	6,600–7,800	5,920	82.3	4.1	76.2–89.4
California	153,900	0.9	151,200–156,700	133,454	86.7	0.9	85.2–88.3
Colorado	14,900	2.6	14,100–15,700	12,973	87.0	2.6	82.7–91.8
Connecticut	11,200	3.3	10,500–11,900	10,346	92.2	3.3	86.7–98.6
Delaware	3,900	5.6	3,500–4,400	3,375	85.9	5.7	77.4–96.5
District of Columbia	14,400	3.0	13,600–15,300	13,604	94.2	3.0	89.1–100
Florida	130,400	1.0	127,800–133,000	113,332	86.9	1.0	85.2–88.7
Georgia	68,600	1.3	66,800–70,400	57,180	83.3	1.3	81.2–85.6
Hawaii	2,600	7.1	2,300–3,000	2,348	89.8	6.0	78.8–100
Idaho <sup>b</sup>	1,700	12.5	1,300–2,100	1,247	74.2	13.3	59.6–98.2
Illinois	40,800	1.8	39,400–42,300	35,353	86.6	1.8	83.7–89.8
Indiana	14,100	2.9	13,300–14,900	11,651	82.7	2.9	78.2–87.8
Iowa	3,400	5.4	3,100–3,800	2,884	84.2	5.5	76.2–94.2
Kansas	4,000	5.6	3,600–4,400	3,258	81.4	5.7	73.4–91.5
Kentucky	9,400	3.5	8,800–10,100	7,689	81.5	3.5	76.3–87.5
Louisiana	25,000	2.3	23,900–26,100	21,043	84.1	2.3	80.5–88.1
Maine	1,800	8.1	1,600–2,100	1,628	88.0	7.0	76.0–100
Maryland	36,600	1.8	35,300–37,900	32,934	90.0	1.8	86.9–93.3
Massachusetts	22,600	2.2	21,600–23,600	20,645	91.3	2.2	87.5–95.5
Michigan	19,200	2.6	18,300–20,200	16,616	86.3	2.6	82.2–90.9
Minnesota	10,100	3.1	9,400–10,700	8,842	87.9	3.2	82.8–93.7
Mississippi <sup>b,c</sup>	11,500	3.4	10,700–12,300	9,501	82.7	3.4	77.5–88.5
Missouri	14,500	2.8	13,700–15,200	12,684	87.8	2.8	83.2–92.8
Montana	740	10.5	670–890	674	91.2	6.8	75.6–100
Nebraska	2,700	6.4	2,400–3,000	2,269	84.2	6.5	74.9–96.3
Nevada	13,300	2.9	12,600–14,000	10,862	81.7	2.9	77.3–86.5
New Hampshire	1,400	8.4	1,300–1,700	1,293	89.5	6.6	76.8–100
New Jersey <sup>b</sup>	38,700	2.1	37,100–40,300	34,068	88.0	2.1	84.6–91.8
New Mexico	4,400	4.6	4,000–4,900	3,850	86.6	4.7	79.4–95.3
New York	131,400	1.0	128,800–133,900	121,890	92.8	1.0	91.0–94.6
North Carolina	38,600	1.7	37,400–39,900	33,020	85.4	1.7	82.7–88.3
North Dakota	740	13.9	530–940	510	69.3	15.1	54.4–95.4
Ohio	27,500	2.1	26,400–28,600	23,242	84.6	2.1	81.3–88.2
Oklahoma	8,200	3.9	7,600–8,800	6,527	79.6	3.9	74.0–86.2
Oregon	8,300	3.7	7,700–8,800	7,265	88.0	3.7	82.1–94.8
Pennsylvania	39,900	1.7	38,500–41,200	35,817	89.8	1.7	86.9–93.0
Puerto Rico <sup>b</sup>	16,900	3.3	15,800–18,000	15,253	90.3	3.3	84.7–96.5
Rhode Island	2,900	5.9	2,600–3,200	2,620	90.8	5.2	81.3–100
South Carolina <sup>c</sup>	20,900	2.4	19,900–21,900	17,486	83.6	2.4	79.8–87.8
South Dakota	820	11.9	680–1,000	678	82.8	10.1	67.2–100
Tennessee	21,500	2.3	20,500–22,500	18,135	84.4	2.3	80.8–88.5
Texas	117,300	1.0	115,000–119,700	96,696	82.4	1.0	80.8–84.1
Utah <sup>c</sup>	3,900	5.2	3,500–4,300	3,226	82.4	5.3	74.8–91.9
Vermont	740	10.5	700–890	697	93.9	6.0	77.9–100
Virginia	27,200	2.1	26,100–28,400	23,468	86.2	2.1	82.7–89.9
Washington	16,300	2.7	15,400–17,100	14,068	86.5	2.7	82.2–91.4
West Virginia <sup>b</sup>	2,800	7.8	2,400–3,300	2,071	73.1	8.0	63.3–86.4
Wisconsin	7,600	3.9	7,100–8,200	6,508	85.2	3.9	79.2–92.2
Wyoming	400	16.8	350–530	346	87.6	9.9	65.9–100

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2021<sup>d</sup></b>						
Alabama	17,200	2.8	16,200–18,100	14,215	82.8	2.8	78.5–87.6
Alaska	920	12.9	740–1,200	744	80.8	11.2	64.5–100
Arizona	21,800	2.7	20,600–22,900	17,961	82.5	2.7	78.3–87.1
Arkansas	7,400	4.2	6,800–8,100	6,137	82.4	4.2	76.2–89.7
California	155,400	0.9	152,600–158,300	135,387	87.1	0.9	85.5–88.7
Colorado	15,300	2.7	14,500–16,100	13,263	86.9	2.7	82.5–91.8
Connecticut	11,200	3.3	10,500–11,900	10,401	92.8	3.4	87.1–99.3
Delaware	4,000	5.8	3,500–4,400	3,429	86.1	5.8	77.4–97.1
District of Columbia	14,200	3.0	13,400–15,100	13,440	94.6	2.9	89.2–100
Florida	132,700	1.0	130,000–135,400	115,881	87.3	1.0	85.6–89.1
Georgia	69,900	1.4	68,000–71,900	58,753	84.0	1.4	81.7–86.4
Hawaii	2,600	7.2	2,400–3,000	2,373	90.0	6.0	78.8–100
Idaho <sup>b</sup>	1,700	12.9	1,300–2,100	1,285	75.5	13.4	60.3–100
Illinois	40,600	1.9	39,100–42,200	35,321	86.9	1.9	83.8–90.3
Indiana	14,600	3.0	13,800–15,500	12,131	83.1	3.0	78.5–88.2
Iowa	3,600	5.5	3,200–4,000	3,005	84.2	5.6	76.0–94.5
Kansas	4,200	5.7	3,700–4,700	3,437	82.0	5.7	73.8–92.2
Kentucky	9,800	3.7	9,100–10,500	7,986	81.7	3.7	76.2–88.1
Louisiana	25,200	2.4	24,000–26,400	21,278	84.4	2.4	80.6–88.5
Maine	1,900	8.2	1,700–2,200	1,668	88.6	6.9	76.2–100
Maryland	36,600	1.9	35,200–37,900	33,017	90.3	1.9	87.1–93.7
Massachusetts	22,700	2.2	21,700–23,700	20,781	91.6	2.3	87.7–95.8
Michigan	19,700	2.6	18,700–20,700	17,056	86.7	2.6	82.5–91.3
Minnesota	10,200	3.2	9,600–10,900	9,051	88.6	3.2	83.4–94.6
Mississippi <sup>b,c</sup>	11,700	3.5	10,900–12,500	9,694	82.5	3.5	77.3–88.6
Missouri	14,700	2.8	13,900–15,500	12,905	87.9	2.8	83.3–93.0
Montana	780	10.4	710–940	712	91.6	6.7	76.1–100
Nebraska	2,800	6.6	2,400–3,100	2,327	84.4	6.7	74.8–96.9
Nevada	13,800	3.0	13,000–14,600	11,288	82.0	3.0	77.5–87.0
New Hampshire	1,500	8.5	1,300–1,700	1,336	90.1	6.4	77.3–100
New Jersey <sup>b</sup>	38,800	2.2	37,200–40,500	34,279	88.3	2.2	84.7–92.2
New Mexico	4,600	4.8	4,100–5,000	3,977	87.1	4.8	79.7–96.1
New York	130,600	1.0	128,000–133,100	121,581	93.1	1.0	91.3–95.0
North Carolina	39,300	1.7	38,000–40,600	33,829	86.1	1.7	83.3–89.0
North Dakota	780	15.3	550–1,000	524	67.2	16.9	51.7–96.1
Ohio	28,000	2.2	26,800–29,200	23,737	84.8	2.2	81.4–88.6
Oklahoma	8,500	4.0	7,900–9,200	6,843	80.0	4.0	74.3–86.8
Oregon	8,400	3.8	7,800–9,000	7,411	88.2	3.9	82.0–95.4
Pennsylvania	40,100	1.8	38,700–41,500	36,204	90.4	1.8	87.3–93.6
Puerto Rico <sup>b</sup>	16,900	3.4	15,800–18,000	15,325	90.7	3.4	85.1–97.2
Rhode Island	2,900	6.0	2,700–3,300	2,663	91.1	5.2	81.5–100
South Carolina <sup>c</sup>	21,200	2.5	20,100–22,200	17,795	84.0	2.6	80.0–88.4
South Dakota	860	12.1	710–1,100	707	82.0	10.5	66.3–100
Tennessee	21,800	2.4	20,800–22,900	18,528	84.8	2.4	81.0–89.0
Texas	120,500	1.1	118,100–123,000	100,041	83.0	1.1	81.3–84.7
Utah <sup>c</sup>	4,100	5.3	3,700–4,500	3,398	83.0	5.4	75.1–92.7
Vermont	760	10.4	720–910	715	94.4	5.8	78.4–100
Virginia	27,600	2.2	26,400–28,800	23,929	86.7	2.2	83.2–90.5
Washington	16,600	2.8	15,700–17,500	14,377	86.7	2.8	82.1–91.7
West Virginia <sup>b</sup>	2,900	8.5	2,400–3,400	2,149	73.5	8.7	63.1–88.1
Wisconsin	7,800	4.0	7,200–8,400	6,713	85.8	4.0	79.6–93.0
Wyoming	420	16.7	370–560	365	86.7	10.2	65.4–100

**Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—United States and Puerto Rico (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2022<sup>d</sup></b>						
Alabama	17,600	2.9	16,600–18,600	14,638	83.0	2.9	78.5–88.0
Alaska	930	14.1	760–1,200	761	81.6	11.3	63.9–100
Arizona	22,300	2.9	21,000–23,500	18,510	83.2	2.9	78.6–88.2
Arkansas	7,700	4.4	7,100–8,400	6,312	81.7	4.4	75.2–89.4
California	157,600	1.0	154,700–160,600	137,764	87.4	1.0	85.8–89.1
Colorado	15,700	2.8	14,800–16,500	13,591	86.8	2.8	82.2–91.8
Connecticut	11,300	3.4	10,500–12,000	10,460	92.7	3.4	86.9–99.4
Delaware	4,100	5.8	3,700–4,600	3,597	87.2	5.8	78.3–98.3
District of Columbia	14,200	3.1	13,400–15,000	13,435	94.9	2.8	89.4–100
Florida	135,400	1.1	132,600–138,200	119,014	87.9	1.1	86.1–89.8
Georgia	71,500	1.5	69,400–73,600	60,382	84.4	1.5	82.0–87.0
Hawaii	2,700	7.4	2,400–3,100	2,422	89.5	6.2	78.2–100
Idaho <sup>b</sup>	1,700	13.5	1,300–2,200	1,341	76.9	13.0	60.7–100
Illinois	41,100	2.0	39,500–42,700	35,863	87.3	2.0	84.0–90.8
Indiana	15,100	3.1	14,200–16,000	12,633	83.6	3.1	78.9–88.9
Iowa	3,800	5.6	3,300–4,200	3,168	84.4	5.7	76.0–94.9
Kansas	4,300	5.9	3,800–4,800	3,567	82.6	5.9	74.1–93.3
Kentucky	10,200	3.9	9,400–11,000	8,393	82.4	3.9	76.6–89.2
Louisiana	25,500	2.5	24,300–26,700	21,637	84.8	2.5	80.9–89.2
Maine	2,000	8.2	1,700–2,300	1,749	88.8	6.8	76.4–100
Maryland	36,500	1.9	35,100–37,900	33,054	90.6	1.9	87.3–94.2
Massachusetts	22,900	2.3	21,900–23,900	20,999	91.7	2.3	87.8–96.1
Michigan	20,000	2.7	19,000–21,100	17,384	86.8	2.7	82.5–91.6
Minnesota	10,400	3.3	9,800–11,100	9,321	89.2	3.3	83.8–95.4
Mississippi <sup>b,c</sup>	11,900	3.7	11,000–12,700	9,807	82.7	3.7	77.1–89.2
Missouri	15,000	2.9	14,100–15,800	13,158	88.0	2.9	83.3–93.3
Montana	790	11.5	710–970	713	90.2	7.5	73.5–100
Nebraska	2,900	7.1	2,500–3,300	2,392	83.8	7.2	73.6–97.2
Nevada	14,100	3.1	13,300–15,000	11,670	82.5	3.1	77.7–87.8
New Hampshire	1,500	8.7	1,400–1,800	1,358	90.6	6.4	77.3–100
New Jersey <sup>b</sup>	39,200	2.2	37,500–40,900	34,807	88.7	2.2	85.0–92.7
New Mexico	4,600	5.2	4,100–5,100	4,004	87.3	5.2	79.3–97.1
New York	131,200	1.0	128,500–133,800	122,482	93.4	1.0	91.5–95.3
North Carolina	39,900	1.8	38,500–41,300	34,612	86.8	1.8	83.9–89.9
North Dakota	830	16.8	550–1,100	536	64.7	18.9	48.6–96.6
Ohio	28,500	2.3	27,200–29,800	24,250	85.2	2.3	81.4–89.2
Oklahoma	8,900	4.1	8,200–9,600	7,189	80.8	4.1	74.8–87.8
Oregon	8,500	4.0	7,800–9,100	7,498	88.7	4.1	82.2–96.3
Pennsylvania	40,400	1.8	38,900–41,800	36,639	90.7	1.8	87.6–94.1
Puerto Rico <sup>b</sup>	16,800	3.5	15,700–18,000	15,366	91.3	3.5	85.5–97.9
Rhode Island	2,900	6.1	2,700–3,300	2,705	92.1	4.9	82.2–100
South Carolina <sup>c</sup>	21,700	2.7	20,500–22,800	18,252	84.2	2.7	80.0–88.9
South Dakota	910	12.4	750–1,100	752	82.5	10.4	66.3–100
Tennessee	22,300	2.4	21,300–23,400	19,160	85.7	2.5	81.8–90.1
Texas	125,100	1.1	122,400–127,700	104,581	83.6	1.1	81.9–85.4
Utah <sup>c</sup>	4,300	5.5	3,800–4,700	3,575	84.0	5.6	75.8–94.1
Vermont	780	10.3	740–940	741	94.5	5.8	78.7–100
Virginia	28,200	2.2	27,000–29,400	24,613	87.3	2.2	83.7–91.3
Washington	16,900	3.0	16,000–17,900	14,766	87.1	3.0	82.3–92.5
West Virginia <sup>b</sup>	3,100	10.0	2,500–3,700	2,263	72.5	10.4	60.6–90.3
Wisconsin	8,000	4.1	7,300–8,600	6,860	86.2	4.2	79.7–93.8
Wyoming	440	17.3	370–580	373	85.7	10.7	64.0–100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2022 are preliminary and based on deaths reported to CDC through December 2023. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

<sup>a</sup> Reported to the National HIV Surveillance System.

<sup>b</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico. Areas with a lapse in reporting during 2022: Mississippi and West Virginia.

<sup>c</sup> Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2022.

<sup>d</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2017</b>						
<b>Arizona</b>							
Maricopa County	13,200	2.8	12,500–13,900	10,638	80.5	2.8	76.3–85.2
<b>California</b>							
Alameda County	6,600	4.1	6,100–7,200	5,804	87.4	4.1	81.0–95.0
Los Angeles County	54,000	1.4	52,500–55,500	47,814	88.5	1.4	86.1–91.0
Orange County	8,400	3.6	7,800–9,000	6,708	80.2	3.6	74.9–86.4
Riverside County	9,700	2.6	9,200–10,200	8,444	86.9	2.6	82.6–91.6
Sacramento County	5,000	4.3	4,600–5,400	4,170	83.4	4.4	76.8–91.2
San Bernardino County	5,500	4.3	5,000–5,900	4,080	74.3	4.3	68.6–81.2
San Diego County	15,100	2.6	14,400–15,900	12,831	84.8	2.6	80.7–89.4
San Francisco County	13,100	3.6	12,300–14,000	12,263	93.6	3.4	87.4–100
<b>District of Columbia</b>	15,000	2.7	14,200–15,800	14,000	93.3	2.7	88.5–98.5
<b>Florida</b>							
Broward County	20,800	2.2	19,900–21,700	19,014	91.3	2.2	87.5–95.4
Duval County	7,500	3.9	6,900–8,000	5,824	78.0	3.9	72.4–84.5
Hillsborough County	8,200	3.7	7,600–8,800	6,610	80.2	3.7	74.8–86.4
Miami-Dade County	28,800	2.1	27,600–30,000	25,613	89.0	2.1	85.5–92.8
Orange County	10,200	3.3	9,600–10,900	8,278	80.9	3.3	76.0–86.5
Palm Beach County	9,000	3.7	8,400–9,700	7,722	85.6	3.7	79.8–92.3
Pinellas County	5,500	4.3	5,000–5,900	4,489	82.2	4.3	75.8–89.8
<b>Georgia</b>							
Cobb County	3,700	4.8	3,300–4,000	2,978	80.8	4.8	73.8–89.1
DeKalb County	9,600	3.2	9,000–10,200	8,090	84.1	3.2	79.1–89.7
Fulton County	16,900	2.4	16,100–17,700	14,184	84.1	2.4	80.3–88.3
Gwinnett County	3,400	4.6	3,100–3,700	2,707	79.1	4.7	72.5–87.0
<b>Illinois</b>							
Cook County	28,600	2.0	27,400–29,700	24,526	85.9	2.0	82.6–89.4
<b>Indiana</b>							
Marion County	5,400	4.2	4,900–5,800	4,476	83.3	4.2	77.0–90.8
<b>Louisiana</b>							
East Baton Rouge Parish	4,500	4.8	4,100–4,900	3,779	84.4	4.9	77.1–93.2
Orleans Parish	5,200	5.2	4,700–5,800	4,715	89.9	5.2	81.7–100
<b>Maryland</b>							
Baltimore City	11,900	3.4	11,100–12,700	10,846	91.4	3.4	85.7–97.9
Montgomery County	4,200	4.9	3,800–4,600	3,758	90.0	5.0	82.1–99.6
Prince George's County	8,900	3.3	8,300–9,500	7,584	85.1	3.3	79.9–91.1
<b>Massachusetts</b>							
Suffolk County	6,100	4.2	5,700–6,600	5,667	92.3	4.1	85.2–100
<b>Michigan</b>							
Wayne County	7,500	4.2	6,900–8,100	6,345	84.9	4.2	78.4–92.4



**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2017 (cont)</b>						
<b>Nevada</b>							
Clark County	9,800	3.0	9,300–10,400	7,929	80.7	3.0	76.2–85.6
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,900	4.0	9,100–10,600	8,813	89.3	4.0	82.8–96.9
Hudson County <sup>b</sup>	5,400	5.3	4,900–6,000	4,698	86.4	5.3	78.3–96.4
<b>New York</b>							
Bronx County	28,300	1.8	27,300–29,300	26,412	93.4	1.8	90.3–96.8
Kings County	27,800	2.0	26,700–28,900	25,489	91.8	2.0	88.3–95.6
New York County	28,000	2.1	26,900–29,200	26,413	94.2	2.2	90.4–98.3
Queens County	17,000	2.5	16,100–17,800	15,267	90.0	2.5	85.7–94.6
<b>North Carolina</b>							
Mecklenburg County	6,600	3.8	6,100–7,100	5,589	84.7	3.8	78.8–91.5
<b>Ohio</b>							
Cuyahoga County	5,100	4.4	4,600–5,500	4,549	89.5	4.5	82.3–98.1
Franklin County	5,700	4.1	5,200–6,100	4,688	82.8	4.1	76.6–90.1
Hamilton County	3,700	5.2	3,300–4,100	2,848	76.7	5.2	69.6–85.3
<b>Pennsylvania</b>							
Philadelphia County	18,400	2.4	17,500–19,200	16,708	91.0	2.4	86.9–95.5
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	3,600	7.6	3,200–4,200	3,170	87.6	6.9	76.3–100
<b>Tennessee</b>							
Shelby County	7,200	3.8	6,700–7,800	6,039	83.7	3.8	77.9–90.5
<b>Texas</b>							
Bexar County	7,500	3.7	7,000–8,100	6,072	80.6	3.7	75.2–86.8
Dallas County	21,100	2.2	20,200–22,000	17,277	81.8	2.2	78.5–85.5
Harris County	29,900	1.9	28,800–31,000	24,599	82.3	1.9	79.3–85.5
Tarrant County	6,800	3.8	6,300–7,200	5,404	80.1	3.8	74.6–86.4
Travis County	5,700	4.3	5,200–6,200	4,694	82.7	4.3	76.3–90.2
<b>Washington</b>							
King County	7,900	3.8	7,300–8,400	6,731	85.6	3.8	79.7–92.5
<b>Total</b>	<b>606,800</b>	<b>0.4</b>	<b>601,700–611,900</b>	<b>527,346</b>	<b>86.9</b>	<b>0.4</b>	<b>86.2–87.6</b>

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2018</b>						
<b>Arizona</b>							
Maricopa County	13,700	2.8	12,900–14,400	11,064	80.9	2.9	76.6–85.7
<b>California</b>							
Alameda County	6,800	4.1	6,200–7,300	5,977	88.3	4.1	81.8–96.0
Los Angeles County	54,500	1.4	53,000–56,000	48,636	89.2	1.4	86.8–91.8
Orange County	8,500	3.7	7,900–9,100	6,813	80.2	3.7	74.9–86.4
Riverside County	10,300	2.6	9,800–10,900	8,994	87.1	2.6	82.9–91.7
Sacramento County	5,200	4.4	4,800–5,600	4,301	82.7	4.4	76.2–90.4
San Bernardino County	5,900	4.2	5,400–6,300	4,415	75.4	4.2	69.7–82.2
San Diego County	15,400	2.6	14,600–16,200	13,021	84.6	2.6	80.5–89.2
San Francisco County	12,900	3.8	12,100–13,800	12,074	93.7	3.5	87.2–100
<b>District of Columbia</b>	14,800	2.8	14,000–15,700	13,877	93.5	2.8	88.6–98.9
<b>Florida</b>							
Broward County	20,900	2.2	20,000–21,900	19,300	92.2	2.2	88.3–96.4
Duval County	7,700	3.9	7,100–8,300	6,013	78.1	4.0	72.5–84.6
Hillsborough County	8,400	3.7	7,800–9,000	6,757	80.3	3.8	74.8–86.6
Miami-Dade County	28,800	2.2	27,600–30,100	25,907	89.8	2.2	86.2–93.8
Orange County	10,500	3.3	9,800–11,100	8,536	81.6	3.3	76.6–87.3
Palm Beach County	9,100	3.7	8,400–9,800	7,781	85.4	3.8	79.6–92.2
Pinellas County	5,500	4.4	5,000–6,000	4,533	82.1	4.4	75.6–89.9
<b>Georgia</b>							
Cobb County	3,900	4.8	3,500–4,200	3,153	81.8	4.9	74.7–90.3
DeKalb County	10,000	3.2	9,400–10,600	8,452	84.5	3.2	79.5–90.2
Fulton County	17,700	2.4	16,900–18,500	15,011	84.9	2.4	81.1–89.1
Gwinnett County	3,500	4.7	3,200–3,900	2,840	80.1	4.8	73.3–88.3
<b>Illinois</b>							
Cook County	28,700	2.1	27,500–29,900	24,813	86.4	2.1	83.1–90.1
<b>Indiana</b>							
Marion County	5,500	4.2	5,100–6,000	4,604	83.3	4.3	76.9–90.8
<b>Louisiana</b>							
East Baton Rouge Parish	4,600	4.9	4,100–5,000	3,843	84.5	4.9	77.1–93.4
Orleans Parish	5,300	5.2	4,800–5,800	4,809	90.8	4.9	82.5–100
<b>Maryland</b>							
Baltimore City	11,000	3.7	10,200–11,800	10,031	90.9	3.7	84.8–97.9
Montgomery County	4,200	5.0	3,800–4,600	3,814	91.0	4.8	82.9–100
Prince George's County	9,100	3.3	8,500–9,700	7,844	86.2	3.4	80.9–92.3
<b>Massachusetts</b>							
Suffolk County	6,100	4.3	5,600–6,600	5,615	92.7	4.0	85.4–100
<b>Michigan</b>							
Wayne County	7,800	4.1	7,100–8,400	6,664	85.9	4.1	79.5–93.5

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2018 (cont)</b>						
<b>Nevada</b>							
Clark County	10,400	2.9	9,800–11,000	8,434	81.2	2.9	76.8–86.2
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,800	4.1	9,000–10,600	8,776	89.8	4.1	83.1–97.7
Hudson County <sup>b</sup>	5,400	5.4	4,900–6,000	4,708	86.6	5.5	78.3–96.9
<b>New York</b>							
Bronx County	28,400	1.8	27,400–29,400	26,595	93.8	1.8	90.6–97.2
Kings County	27,800	2.0	26,700–29,000	25,643	92.1	2.0	88.6–96.0
New York County	28,000	2.2	26,800–29,200	26,405	94.3	2.2	90.5–98.5
Queens County	17,000	2.5	16,200–17,900	15,490	90.9	2.5	86.6–95.7
<b>North Carolina</b>							
Mecklenburg County	6,800	3.8	6,300–7,300	5,781	84.7	3.8	78.8–91.5
<b>Ohio</b>							
Cuyahoga County	5,200	4.5	4,700–5,600	4,664	90.4	4.5	83.1–99.1
Franklin County	5,700	4.2	5,200–6,200	4,743	82.9	4.2	76.6–90.4
Hamilton County	3,700	5.3	3,300–4,100	2,882	77.5	5.4	70.1–86.6
<b>Pennsylvania</b>							
Philadelphia County	18,300	2.5	17,400–19,200	16,642	91.1	2.5	86.9–95.7
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	3,600	7.6	3,200–4,200	3,206	88.1	6.8	76.7–100
<b>Tennessee</b>							
Shelby County	7,400	3.8	6,900–8,000	6,299	84.6	3.8	78.8–91.4
<b>Texas</b>							
Bexar County	7,700	3.7	7,100–8,300	6,251	81.2	3.7	75.7–87.5
Dallas County	21,800	2.2	20,900–22,800	17,914	82.0	2.2	78.6–85.7
Harris County	30,600	1.9	29,400–31,700	25,386	83.1	1.9	80.1–86.3
Tarrant County	7,000	3.8	6,500–7,500	5,637	80.3	3.8	74.8–86.7
Travis County	5,900	4.2	5,400–6,400	4,885	82.8	4.3	76.5–90.3
<b>Washington</b>							
King County	7,900	3.9	7,300–8,500	6,795	86.1	3.9	80.0–93.3
<b>Total</b>	<b>614,700</b>	<b>0.4</b>	<b>609,500–620,000</b>	<b>536,628</b>	<b>87.3</b>	<b>0.4</b>	<b>86.6–88.0</b>

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2019</b>						
<b>Arizona</b>							
Maricopa County	14,100	2.9	13,300–15,000	11,522	81.4	2.9	77.0–86.4
<b>California</b>							
Alameda County	6,800	4.2	6,200–7,300	6,028	88.8	4.2	82.1–96.7
Los Angeles County	55,000	1.5	53,500–56,600	49,414	89.8	1.5	87.3–92.4
Orange County	8,600	3.7	8,000–9,200	6,905	80.1	3.7	74.7–86.4
Riverside County	10,700	2.6	10,200–11,300	9,358	87.2	2.6	82.9–91.8
Sacramento County	5,300	4.4	4,900–5,800	4,407	82.5	4.5	75.9–90.4
San Bernardino County	6,100	4.2	5,600–6,600	4,683	76.3	4.3	70.4–83.2
San Diego County	15,600	2.7	14,800–16,400	13,176	84.6	2.7	80.4–89.3
San Francisco County	12,700	3.9	12,000–13,600	11,950	94.3	3.4	87.6–100
<b>District of Columbia</b>	14,800	2.9	13,900–15,600	13,846	93.8	2.9	88.9–99.4
<b>Florida</b>							
Broward County	21,100	2.3	20,100–22,000	19,605	93.1	2.3	89.1–97.4
Duval County	7,800	4.0	7,200–8,400	6,152	78.6	4.0	72.9–85.3
Hillsborough County	8,700	3.8	8,000–9,300	6,973	80.3	3.8	74.8–86.7
Miami-Dade County	28,900	2.2	27,600–30,100	26,144	90.5	2.2	86.8–94.6
Orange County	10,700	3.4	10,000–11,400	8,742	81.6	3.4	76.5–87.5
Palm Beach County	9,300	3.8	8,600–9,900	7,872	85.0	3.8	79.1–91.9
Pinellas County	5,700	4.4	5,300–6,200	4,740	82.4	4.5	75.9–90.3
<b>Georgia</b>							
Cobb County	4,000	5.0	3,600–4,400	3,312	82.1	5.0	74.9–91.0
DeKalb County	10,400	3.3	9,700–11,000	8,825	85.2	3.3	80.1–91.0
Fulton County	18,200	2.4	17,300–19,000	15,524	85.4	2.4	81.6–89.7
Gwinnett County	3,700	4.9	3,400–4,100	3,043	81.6	5.0	74.4–90.4
<b>Illinois</b>							
Cook County	29,300	2.1	28,100–30,500	25,475	87.0	2.1	83.6–90.8
<b>Indiana</b>							
Marion County	5,500	4.4	5,100–6,000	4,600	82.9	4.4	76.3–90.7
<b>Louisiana</b>							
East Baton Rouge Parish	4,600	5.0	4,200–5,100	3,877	84.2	5.0	76.7–93.3
Orleans Parish	5,300	5.2	4,900–5,900	4,901	91.8	4.6	83.3–100
<b>Maryland</b>							
Baltimore City	11,000	3.7	10,200–11,800	10,015	91.3	3.8	85.1–98.6
Montgomery County	4,200	5.1	3,900–4,600	3,853	92.0	4.5	83.6–100
Prince George's County	9,100	3.4	8,500–9,700	7,938	87.0	3.4	81.5–93.3
<b>Massachusetts</b>							
Suffolk County	6,000	4.4	5,600–6,600	5,614	92.9	4.0	85.6–100
<b>Michigan</b>							
Wayne County	7,900	4.1	7,300–8,600	6,872	86.5	4.1	80.1–94.1

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2019 (cont)</b>						
<b>Nevada</b>							
Clark County	10,800	3.0	10,200–11,500	8,867	81.8	3.0	77.3–86.9
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,700	4.2	8,900–10,500	8,774	90.1	4.2	83.2–98.2
Hudson County <sup>b</sup>	5,400	5.5	4,800–6,000	4,744	87.4	5.6	78.9–98.0
<b>New York</b>							
Bronx County	28,700	1.8	27,600–29,700	27,026	94.3	1.8	91.1–97.8
Kings County	27,800	2.1	26,700–28,900	25,644	92.3	2.1	88.7–96.2
New York County	27,800	2.2	26,600–29,000	26,214	94.4	2.2	90.5–98.7
Queens County	17,100	2.6	16,300–18,000	15,681	91.5	2.6	87.1–96.4
<b>North Carolina</b>							
Mecklenburg County	7,100	3.8	6,600–7,600	5,998	84.4	3.8	78.5–91.2
<b>Ohio</b>							
Cuyahoga County	5,200	4.5	4,700–5,700	4,740	91.3	4.5	83.8–100
Franklin County	5,900	4.2	5,500–6,400	4,973	83.6	4.2	77.3–91.1
Hamilton County	3,800	5.4	3,400–4,200	3,016	79.0	5.5	71.4–88.4
<b>Pennsylvania</b>							
Philadelphia County	18,400	2.5	17,500–19,300	16,794	91.2	2.5	87.0–95.9
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	3,700	7.6	3,300–4,200	3,267	88.5	6.6	77.0–100
<b>Tennessee</b>							
Shelby County	7,500	3.9	7,000–8,100	6,340	84.3	3.9	78.3–91.2
<b>Texas</b>							
Bexar County	8,000	3.8	7,400–8,600	6,495	81.2	3.8	75.6–87.6
Dallas County	22,300	2.2	21,300–23,300	18,454	82.7	2.2	79.2–86.4
Harris County	31,400	1.9	30,200–32,600	26,336	84.0	1.9	80.9–87.3
Tarrant County	7,400	3.8	6,800–7,900	5,885	79.8	3.9	74.3–86.3
Travis County	6,000	4.3	5,500–6,500	5,026	83.6	4.3	77.1–91.2
<b>Washington</b>							
King County	8,000	4.0	7,400–8,600	6,960	86.8	4.0	80.6–94.1
<b>Total</b>	<b>623,400</b>	<b>0.4</b>	<b>618,000–628,800</b>	<b>546,600</b>	<b>87.7</b>	<b>0.4</b>	<b>86.9–88.4</b>

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2020 (COVID-19 pandemic)<sup>c</sup></b>						
<b>Arizona</b>							
Maricopa County	14,500	3.2	13,600–15,400	11,876	82.0	3.2	77.2–87.4
<b>California</b>							
Alameda County	6,700	4.3	6,100–7,300	5,958	89.1	4.4	82.1–97.4
Los Angeles County	55,100	1.5	53,500–56,800	49,813	90.4	1.5	87.8–93.1
Orange County	8,800	3.8	8,100–9,400	7,021	80.0	3.9	74.4–86.5
Riverside County	11,100	2.6	10,500–11,700	9,712	87.3	2.7	83.0–92.1
Sacramento County	5,500	4.5	5,000–5,900	4,535	83.1	4.6	76.4–91.2
San Bernardino County	6,300	4.4	5,700–6,800	4,797	76.4	4.5	70.4–83.7
San Diego County	15,700	2.7	14,900–16,600	13,301	84.6	2.7	80.3–89.4
San Francisco County	12,400	4.0	11,800–13,400	11,756	94.8	3.3	87.9–100
<b>District of Columbia</b>	14,400	3.0	13,600–15,300	13,604	94.2	3.0	89.1–100
<b>Florida</b>							
Broward County	21,100	2.3	20,100–22,100	19,786	93.8	2.3	89.7–98.3
Duval County	8,000	4.2	7,400–8,700	6,259	78.0	4.2	72.1–85.0
Hillsborough County	8,900	3.9	8,200–9,500	7,179	80.9	3.9	75.2–87.5
Miami-Dade County	28,800	2.3	27,500–30,100	26,243	91.0	2.3	87.1–95.3
Orange County	10,800	3.6	10,100–11,600	8,871	81.9	3.6	76.6–88.1
Palm Beach County	9,400	3.9	8,700–10,100	7,935	84.2	4.0	78.2–91.3
Pinellas County	5,900	4.6	5,400–6,400	4,856	82.2	4.6	75.4–90.4
<b>Georgia</b>							
Cobb County	4,200	5.3	3,800–4,700	3,468	82.3	5.3	74.6–91.8
DeKalb County	10,500	3.4	9,800–11,200	8,990	85.7	3.4	80.4–91.9
Fulton County	18,500	2.5	17,600–19,500	15,900	85.8	2.6	81.7–90.3
Gwinnett County	3,800	5.3	3,400–4,200	3,180	83.4	5.3	75.6–93.0
<b>Illinois</b>							
Cook County	29,300	2.2	28,100–30,600	25,631	87.4	2.2	83.8–91.3
<b>Indiana</b>							
Marion County	5,700	4.5	5,200–6,200	4,711	83.0	4.6	76.2–91.1
<b>Louisiana</b>							
East Baton Rouge Parish	4,700	5.0	4,300–5,200	4,033	85.3	5.1	77.6–94.5
Orleans Parish	5,300	5.4	4,900–5,800	4,856	92.1	4.6	83.3–100
<b>Maryland</b>							
Baltimore City	11,100	3.7	10,300–11,900	10,189	91.6	3.8	85.3–98.9
Montgomery County	4,200	5.3	3,900–4,600	3,859	92.5	4.5	83.8–100
Prince George's County	9,100	3.5	8,500–9,800	8,018	87.8	3.5	82.1–94.3
<b>Massachusetts</b>							
Suffolk County	6,100	4.4	5,600–6,600	5,624	92.9	4.0	85.4–100
<b>Michigan</b>							
Wayne County	8,000	4.2	7,400–8,700	6,944	86.4	4.2	79.8–94.2

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2020 (COVID-19 pandemic)<sup>c</sup> (cont)</b>						
<b>Nevada</b>							
Clark County	11,300	3.0	10,600–12,000	9,227	81.6	3.1	77.0–86.7
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,600	4.4	8,800–10,400	8,688	90.5	4.4	83.3–98.9
Hudson County <sup>b</sup>	5,400	5.7	4,800–6,000	4,719	87.5	5.8	78.6–98.5
<b>New York</b>							
Bronx County	28,300	1.9	27,300–29,300	26,694	94.3	1.9	91.0–97.9
Kings County	27,500	2.1	26,400–28,700	25,460	92.6	2.1	88.8–96.6
New York County	27,300	2.3	26,100–28,500	25,818	94.7	2.3	90.7–99.1
Queens County	17,000	2.6	16,100–17,900	15,662	92.1	2.6	87.6–97.1
<b>North Carolina</b>							
Mecklenburg County	7,200	3.9	6,700–7,800	6,101	84.4	3.9	78.4–91.4
<b>Ohio</b>							
Cuyahoga County	5,200	4.7	4,800–5,700	4,837	92.3	4.3	84.5–100
Franklin County	6,000	4.3	5,500–6,600	5,110	84.6	4.3	78.0–92.3
Hamilton County	3,900	5.6	3,500–4,300	3,075	79.0	5.6	71.2–88.7
<b>Pennsylvania</b>							
Philadelphia County	18,100	2.6	17,200–19,100	16,623	91.6	2.6	87.2–96.6
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	3,800	7.6	3,400–4,300	3,352	89.2	6.4	77.6–100
<b>Tennessee</b>							
Shelby County	7,400	4.0	6,800–8,000	6,267	84.5	4.1	78.3–91.8
<b>Texas</b>							
Bexar County	8,200	3.9	7,600–8,900	6,726	81.7	3.9	75.9–88.4
Dallas County	22,700	2.3	21,600–23,700	18,889	83.3	2.3	79.7–87.3
Harris County	31,800	2.0	30,500–33,000	26,877	84.6	2.0	81.4–88.1
Tarrant County	7,800	4.0	7,100–8,400	6,143	79.2	4.0	73.4–86.0
Travis County	6,100	4.4	5,600–6,600	5,129	84.2	4.4	77.5–92.2
<b>Washington</b>							
King County	8,100	4.1	7,400–8,700	7,014	86.8	4.1	80.4–94.4
<b>Total</b>	<b>626,700</b>	<b>0.5</b>	<b>621,200–632,300</b>	<b>551,316</b>	<b>88.0</b>	<b>0.5</b>	<b>87.2–88.8</b>

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2021<sup>c</sup></b>						
<b>Arizona</b>							
Maricopa County	14,800	3.4	13,800–15,800	12,215	82.4	3.4	77.3–88.3
<b>California</b>							
Alameda County	6,600	4.5	6,000–7,200	5,945	89.6	4.6	82.3–98.3
Los Angeles County	55,100	1.5	53,400–56,800	50,194	91.1	1.5	88.4–94.0
Orange County	8,900	3.9	8,200–9,600	7,163	80.2	4.0	74.5–86.9
Riverside County	11,500	2.7	10,900–12,100	10,135	87.9	2.7	83.5–92.8
Sacramento County	5,500	4.7	5,000–6,000	4,621	83.9	4.7	76.9–92.4
San Bernardino County	6,500	4.6	5,900–7,100	5,000	77.1	4.6	70.7–84.7
San Diego County	15,900	2.8	15,100–16,800	13,486	84.7	2.8	80.2–89.6
San Francisco County	12,200	4.2	11,600–13,200	11,576	95.1	3.2	87.9–100
<b>District of Columbia</b>	14,200	3.0	13,400–15,100	13,440	94.6	2.9	89.2–100
<b>Florida</b>							
Broward County	21,200	2.4	20,200–22,200	20,121	94.8	2.4	90.5–99.5
Duval County	8,300	4.4	7,500–9,000	6,399	77.5	4.4	71.4–84.8
Hillsborough County	9,000	3.9	8,300–9,700	7,386	82.2	4.0	76.3–89.1
Miami-Dade County	29,300	2.3	28,000–30,700	26,840	91.5	2.3	87.5–95.9
Orange County	11,300	3.7	10,500–12,100	9,243	81.9	3.7	76.4–88.2
Palm Beach County	9,500	4.0	8,700–10,200	8,053	84.8	4.1	78.6–92.1
Pinellas County	6,000	4.7	5,500–6,600	4,929	81.7	4.8	74.8–90.1
<b>Georgia</b>							
Cobb County	4,300	5.5	3,900–4,800	3,612	83.5	5.6	75.4–93.7
DeKalb County	10,400	3.6	9,700–11,200	9,050	86.8	3.6	81.1–93.4
Fulton County	18,900	2.7	17,900–19,900	16,265	85.9	2.7	81.6–90.7
Gwinnett County	3,900	5.6	3,500–4,400	3,325	84.6	5.7	76.2–95.1
<b>Illinois</b>							
Cook County	29,100	2.3	27,800–30,400	25,469	87.6	2.3	83.9–91.8
<b>Indiana</b>							
Marion County	5,900	4.6	5,300–6,400	4,899	83.5	4.7	76.6–91.8
<b>Louisiana</b>							
East Baton Rouge Parish	4,700	5.1	4,300–5,200	4,061	85.8	5.2	77.9–95.4
Orleans Parish	5,200	5.6	4,800–5,700	4,763	92.3	4.7	83.1–100
<b>Maryland</b>							
Baltimore City	11,000	3.8	10,200–11,900	10,107	91.6	3.9	85.2–99.0
Montgomery County	4,200	5.4	3,900–4,600	3,886	92.8	4.4	84.0–100
Prince George's County	9,100	3.7	8,400–9,700	8,000	88.0	3.7	82.1–94.8
<b>Massachusetts</b>							
Suffolk County	6,000	4.5	5,600–6,500	5,586	93.0	4.0	85.4–100
<b>Michigan</b>							
Wayne County	8,200	4.2	7,500–8,900	7,157	87.0	4.3	80.3–94.8



**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2021<sup>c</sup> (cont)</b>						
<b>Nevada</b>							
Clark County	11,700	3.1	11,000–12,400	9,591	81.9	3.2	77.2–87.3
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,500	4.5	8,700–10,300	8,621	90.7	4.6	83.3–99.5
Hudson County <sup>b</sup>	5,500	5.8	4,800–6,100	4,798	87.9	5.9	78.9–99.2
<b>New York</b>							
Bronx County	28,000	1.9	26,900–29,000	26,416	94.4	1.9	91.0–98.1
Kings County	27,400	2.2	26,200–28,600	25,435	92.9	2.2	89.1–97.0
New York County	27,000	2.3	25,800–28,200	25,641	95.0	2.3	90.8–99.5
Queens County	17,100	2.7	16,200–18,000	15,827	92.6	2.7	88.0–97.7
<b>North Carolina</b>							
Mecklenburg County	7,300	4.0	6,700–7,900	6,199	85.1	4.1	78.8–92.4
<b>Ohio</b>							
Cuyahoga County	5,300	5.0	4,900–5,800	4,894	92.1	4.4	83.9–100
Franklin County	6,100	4.5	5,600–6,600	5,185	85.0	4.6	78.1–93.3
Hamilton County	3,900	5.9	3,500–4,400	3,118	79.1	6.0	70.9–89.4
<b>Pennsylvania</b>							
Philadelphia County	18,000	2.7	17,000–18,900	16,517	91.9	2.7	87.3–97.0
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	4,000	7.4	3,600–4,600	3,581	89.9	6.1	78.6–100
<b>Tennessee</b>							
Shelby County	7,600	4.1	7,000–8,200	6,506	85.3	4.1	79.0–92.7
<b>Texas</b>							
Bexar County	8,400	4.1	7,700–9,000	6,870	82.1	4.1	76.0–89.2
Dallas County	23,300	2.4	22,200–24,400	19,445	83.5	2.4	79.8–87.6
Harris County	32,200	2.1	30,900–33,600	27,575	85.5	2.1	82.2–89.2
Tarrant County	8,000	4.2	7,400–8,700	6,338	79.0	4.2	73.0–86.1
Travis County	6,100	4.6	5,600–6,700	5,220	85.1	4.6	78.0–93.5
<b>Washington</b>							
King County	8,200	4.2	7,500–8,800	7,104	87.1	4.3	80.4–95.0
<b>Total</b>	<b>631,400</b>	<b>0.5</b>	<b>625,600–637,300</b>	<b>557,807</b>	<b>88.3</b>	<b>0.5</b>	<b>87.5–89.2</b>

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2022<sup>c</sup></b>						
<b>Arizona</b>							
Maricopa County	15,100	3.7	14,000–16,200	12,570	83.3	3.7	77.7–89.7
<b>California</b>							
Alameda County	6,600	4.7	6,000–7,200	5,948	90.1	4.7	82.5–99.3
Los Angeles County	55,400	1.6	53,600–57,100	50,708	91.6	1.6	88.8–94.5
Orange County	9,100	4.0	8,400–9,800	7,282	80.3	4.1	74.4–87.2
Riverside County	11,900	2.8	11,300–12,500	10,544	88.7	2.8	84.1–93.7
Sacramento County	5,600	4.9	5,000–6,100	4,644	83.7	5.0	76.3–92.6
San Bernardino County	6,700	4.7	6,100–7,300	5,200	78.0	4.8	71.4–85.9
San Diego County	16,200	2.9	15,300–17,100	13,684	84.6	2.9	80.1–89.7
San Francisco County	12,100	4.3	11,500–13,100	11,542	95.5	3.2	88.1–100
<b>District of Columbia</b>	14,200	3.1	13,400–15,000	13,435	94.9	2.8	89.4–100
<b>Florida</b>							
Broward County	21,300	2.4	20,500–22,400	20,518	96.2	2.2	91.8–100
Duval County	8,400	4.5	7,700–9,100	6,528	77.7	4.6	71.4–85.3
Hillsborough County	9,200	4.1	8,500–9,900	7,571	82.3	4.1	76.2–89.5
Miami-Dade County	30,100	2.4	28,700–31,500	27,688	92.0	2.4	87.9–96.6
Orange County	11,600	3.8	10,700–12,400	9,497	82.0	3.8	76.3–88.6
Palm Beach County	9,600	4.1	8,900–10,400	8,279	85.9	4.1	79.5–93.4
Pinellas County	6,000	4.9	5,400–6,600	4,921	81.6	5.0	74.5–90.3
<b>Georgia</b>							
Cobb County	4,400	5.8	3,900–4,900	3,744	84.6	5.9	76.0–95.5
DeKalb County	10,600	3.9	9,800–11,400	9,118	86.3	4.0	80.1–93.5
Fulton County	19,000	2.8	17,900–20,000	16,301	86.0	2.9	81.4–91.1
Gwinnett County	4,000	6.0	3,600–4,500	3,498	86.7	6.1	77.6–98.2
<b>Illinois</b>							
Cook County	29,200	2.4	27,900–30,600	25,738	88.0	2.4	84.1–92.3
<b>Indiana</b>							
Marion County	6,000	4.7	5,500–6,600	5,070	84.1	4.8	77.0–92.7
<b>Louisiana</b>							
East Baton Rouge Parish	4,600	5.5	4,100–5,100	3,956	85.6	5.5	77.3–95.8
Orleans Parish	5,100	5.8	4,800–5,700	4,756	92.9	4.5	83.5–100
<b>Maryland</b>							
Baltimore City	11,000	3.9	10,200–11,900	10,103	91.7	3.9	85.2–99.3
Montgomery County	4,200	5.5	4,000–4,700	3,979	93.9	4.1	84.8–100
Prince George's County	9,100	3.8	8,500–9,800	8,077	88.4	3.8	82.3–95.5
<b>Massachusetts</b>							
Suffolk County	6,000	4.7	5,600–6,500	5,559	93.3	4.0	85.4–100
<b>Michigan</b>							
Wayne County	8,300	4.4	7,500–9,000	7,195	87.1	4.4	80.2–95.3

**Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. <sup>a</sup>	%	RSE (%)	95% CI
	<b>2022<sup>c</sup> (cont)</b>						
<b>Nevada</b>							
Clark County	12,100	3.3	11,300–12,900	9,986	82.5	3.3	77.5–88.2
<b>New Jersey</b>							
Essex County <sup>b</sup>	9,500	4.6	8,600–10,300	8,592	90.7	4.7	83.1–99.8
Hudson County <sup>b</sup>	5,600	5.8	4,900–6,200	4,925	88.6	5.9	79.5–100
<b>New York</b>							
Bronx County	28,000	2.0	26,900–29,100	26,402	94.4	2.0	90.9–98.2
Kings County	27,400	2.2	26,200–28,600	25,535	93.1	2.2	89.2–97.4
New York County	26,900	2.3	25,700–28,200	25,680	95.3	2.4	91.1–99.9
Queens County	17,400	2.7	16,500–18,300	16,220	93.2	2.7	88.5–98.4
<b>North Carolina</b>							
Mecklenburg County	7,600	4.1	7,000–8,200	6,605	87.1	4.1	80.7–94.7
<b>Ohio</b>							
Cuyahoga County	5,300	5.3	4,900–5,900	4,937	92.4	4.5	83.6–100
Franklin County	6,200	5.0	5,600–6,800	5,304	85.6	5.1	77.9–94.9
Hamilton County	4,000	6.3	3,500–4,400	3,150	79.6	6.4	70.8–90.9
<b>Pennsylvania</b>							
Philadelphia County	18,000	2.8	17,100–19,000	16,606	92.1	2.8	87.4–97.4
<b>Puerto Rico</b>							
San Juan Municipio <sup>b</sup>	4,100	7.3	3,700–4,700	3,739	91.4	5.6	79.9–100
<b>Tennessee</b>							
Shelby County	7,800	4.2	7,100–8,400	6,715	86.6	4.2	80.0–94.3
<b>Texas</b>							
Bexar County	8,600	4.3	7,800–9,300	7,090	82.9	4.3	76.5–90.5
Dallas County	24,000	2.5	22,900–25,200	20,095	83.6	2.5	79.7–87.9
Harris County	33,000	2.1	31,600–34,400	28,642	86.7	2.1	83.2–90.5
Tarrant County	8,500	4.4	7,700–9,200	6,647	78.6	4.4	72.4–86.0
Travis County	6,200	4.7	5,700–6,800	5,410	86.7	4.8	79.3–95.5
<b>Washington</b>							
King County	8,200	4.5	7,500–8,900	7,223	88.0	4.6	80.8–96.6
<b>Total</b>	<b>638,900</b>	<b>0.5</b>	<b>632,800–645,000</b>	<b>567,156</b>	<b>88.8</b>	<b>0.5</b>	<b>87.9–89.6</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates for the year 2022 are preliminary and based on deaths reported to CDC through December 2023. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

<sup>a</sup> Reported to the National HIV Surveillance System.

<sup>b</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>c</sup> Estimates for years 2020, 2021, and 2022 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2018–2022*, available at <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>, for more information.

**Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2023—United States**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022	2023 (preliminary) <sup>b</sup>
	No.	No.	No.	No.	No.	No.	No.
<b>Gender</b>							
Man	30,166	29,415	28,731	24,177	28,246	29,693	26,957
Woman	7,141	6,952	6,820	5,354	6,445	6,915	6,502
Transgender woman <sup>c</sup>	683	691	720	719	873	868	610
Transgender man <sup>c</sup>	38	48	45	41	60	59	51
Additional gender identity <sup>d</sup>	20	26	34	26	47	66	84
<b>Age at diagnosis (yr)</b>							
13–24	8,286	7,882	7,680	6,167	7,010	7,049	6,081
25–34	13,324	13,297	13,036	11,307	13,068	14,031	12,613
35–44	7,147	7,089	7,007	5,846	7,513	8,283	7,860
45–54	5,497	5,152	4,840	3,872	4,382	4,516	4,217
55–64	2,930	2,845	2,925	2,439	2,871	2,850	2,569
65–74	732	730	729	589	724	737	740
≥75	132	137	133	97	103	135	127
<b>Race/ethnicity</b>							
American Indian/Alaska Native	187	166	180	177	211	215	175
Asian	899	837	712	597	729	795	717
Black/African American	15,908	15,387	15,130	12,533	14,304	14,546	13,484
Hispanic/Latino <sup>e</sup>	9,928	9,934	9,924	8,164	10,135	11,804	10,755
Native Hawaiian/other Pacific Islander	44	53	56	59	73	83	55
White	9,425	9,215	8,887	7,643	8,980	9,102	8,302
Multiracial	1,657	1,540	1,461	1,144	1,239	1,056	719
<b>Transmission category<sup>f</sup></b>							
Male-to-male sexual contact <sup>g</sup>	25,182	24,346	23,827	20,462	23,785	25,193	22,807
Injection drug use <sup>h</sup>							
Male	1,272	1,373	1,371	1,191	1,440	1,465	1,216
Female	1,102	1,134	1,190	886	1,096	1,156	928
Male-to-male sexual contact <sup>g</sup> and injection drug use <sup>h</sup>	1,541	1,567	1,617	1,240	1,437	1,323	1,107
Heterosexual contact <sup>i</sup>							
Male	2,841	2,813	2,628	2,004	2,471	2,605	2,485
Female	6,037	5,830	5,644	4,479	5,380	5,775	5,590
<b>Region of residence<sup>j</sup></b>							
Northeast	5,964	5,543	5,318	4,263	4,892	5,069	4,348
Midwest	5,107	4,936	4,777	4,116	4,828	4,891	4,603
South	19,351	19,029	18,823	15,469	18,603	19,793	18,465
West	7,626	7,624	7,432	6,469	7,348	7,848	6,791
<b>Total<sup>k</sup></b>	<b>38,048</b>	<b>37,132</b>	<b>36,350</b>	<b>30,317</b>	<b>35,671</b>	<b>37,601</b>	<b>34,207</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2023.

<sup>a</sup> Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. Therefore, readers should also consider the potential influence of COVID-19 on HIV data for subsequent years.

<sup>b</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>c</sup> “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

<sup>d</sup> Additional gender identity includes “nonbinary,” “gender queer,” and “two-spirit.”

<sup>e</sup> Hispanic/Latino persons can be of any race.

<sup>f</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>g</sup> Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>h</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>i</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>j</sup> Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of diagnosis of HIV infection.

<sup>k</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful. Includes persons of unknown gender.

**Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017–2023—United States and 6 territories and freely associated states**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022	2023 (preliminary) <sup>b</sup>
	No.	No.	No.	No.	No.	No.	No.
<b>Gender</b>							
Man	30,532	29,791	29,066	24,440	28,585	30,006	27,261
Woman	7,236	7,035	6,901	5,401	6,530	6,981	6,561
Transgender woman <sup>c</sup>	686	694	722	722	874	869	612
Transgender man <sup>c</sup>	38	48	45	41	60	59	51
Additional gender identity <sup>d</sup>	20	26	34	26	47	66	84
<b>Age at diagnosis (yr)</b>							
13–24	8,364	7,965	7,744	6,224	7,071	7,099	6,125
25–34	13,449	13,433	13,152	11,391	13,194	14,160	12,741
35–44	7,235	7,167	7,085	5,911	7,606	8,367	7,933
45–54	5,590	5,247	4,906	3,923	4,456	4,576	4,268
55–64	2,990	2,892	2,989	2,483	2,915	2,886	2,618
65–74	745	750	756	601	748	754	760
≥75	139	140	136	97	106	139	127
<b>Race/ethnicity</b>							
American Indian/Alaska Native	187	166	180	177	211	215	175
Asian	902	841	719	597	730	795	717
Black/African American	15,913	15,399	15,138	12,539	14,310	14,553	13,486
Hispanic/Latino <sup>e</sup>	10,375	10,372	10,317	8,469	10,546	12,167	11,106
Native Hawaiian/other Pacific Islander	47	55	60	60	73	83	55
White	9,429	9,220	8,893	7,644	8,987	9,112	8,313
Multiracial	1,659	1,541	1,461	1,144	1,239	1,056	720
<b>Transmission category<sup>f</sup></b>							
Male-to-male sexual contact <sup>g</sup>	25,426	24,622	24,064	20,662	24,041	25,422	23,038
Injection drug use <sup>h</sup>							
Male	1,305	1,399	1,393	1,210	1,458	1,490	1,232
Female	1,111	1,136	1,195	889	1,098	1,161	929
Male-to-male sexual contact <sup>g</sup> and injection drug use <sup>h</sup>	1,553	1,578	1,629	1,244	1,439	1,327	1,108
Heterosexual contact <sup>i</sup>							
Male	2,921	2,879	2,694	2,047	2,535	2,660	2,543
Female	6,123	5,910	5,720	4,523	5,464	5,835	5,648
<b>Region of residence<sup>j</sup></b>							
Northeast	5,964	5,543	5,318	4,263	4,892	5,069	4,348
Midwest	5,107	4,936	4,777	4,116	4,828	4,891	4,603
South	19,351	19,029	18,823	15,469	18,603	19,793	18,465
West	7,626	7,624	7,432	6,469	7,348	7,848	6,791
U.S. territories and freely associated states	464	462	418	313	425	380	365
<b>Total<sup>k</sup></b>	<b>38,512</b>	<b>37,594</b>	<b>36,768</b>	<b>30,630</b>	<b>36,096</b>	<b>37,981</b>	<b>34,572</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau. Data are for cases reported to CDC through December 2023.

<sup>a</sup> Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. Therefore, readers should also consider the potential influence of COVID-19 on HIV data for subsequent years.

<sup>b</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>c</sup> “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

<sup>d</sup> Additional gender identity includes “nonbinary,” “gender queer,” and “two-spirit.”

<sup>e</sup> Hispanic/Latino persons can be of any race.

<sup>f</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>g</sup> Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>h</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>i</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>j</sup> Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of diagnosis of HIV infection.

<sup>k</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful. Includes persons of unknown gender.

**Table 3c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2023—United States and 6 territories and freely associated states**

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) <sup>a</sup> No.	2021 No.	2022 No.	2023 (preliminary) <sup>b</sup> No.
Alabama	644	606	632	581	661	701	513
Alaska	29	23	27	29	30	38	22
Arizona	714	753	733	648	775	860	829
Arkansas	285	279	288	245	334	305	328
California	4,894	4,808	4,571	4,097	4,539	4,856	4,017
Colorado	431	398	459	326	403	433	422
Connecticut	272	258	206	173	232	220	181
Delaware	123	92	93	91	82	128	105
District of Columbia	310	277	255	196	198	211	207
Florida	4,297	4,190	4,010	3,166	3,892	4,290	4,502
Georgia	2,597	2,498	2,418	1,968	2,285	2,511	2,115
Hawaii	75	72	64	53	71	78	49
Idaho	45	36	34	34	54	41	46
Illinois	1,393	1,375	1,295	1,086	1,195	1,306	1,114
Indiana	514	515	481	430	527	612	605
Iowa	124	115	100	100	124	123	136
Kansas	116	154	132	142	153	133	142
Kentucky	367	377	325	301	388	405	361
Louisiana	975	949	877	710	896	856	846
Maine	29	31	30	15	31	41	32
Maryland	1,011	989	913	708	735	748	651
Massachusetts	598	642	532	428	444	438	313
Michigan	771	717	674	519	641	629	662
Minnesota	280	286	274	231	296	261	301
Mississippi	429	474	467	405	427	448	431
Missouri	504	450	490	367	547	512	539
Montana	30	24	25	14	22	11	22
Nebraska	86	77	80	72	105	91	91
Nevada	497	498	517	394	502	528	516
New Hampshire	32	38	31	32	32	28	32
New Jersey	1,094	1,003	1,076	769	1,032	1,090	805
New Mexico	145	153	176	132	150	94	26
New York	2,736	2,461	2,369	1,992	2,117	2,226	2,075
North Carolina	1,291	1,183	1,356	1,080	1,389	1,353	1,342
North Dakota	39	36	39	36	38	38	17
Ohio	981	974	969	883	919	855	719
Oklahoma	300	277	345	341	385	394	237
Oregon	204	227	198	180	201	250	226
Pennsylvania	1,097	1,017	991	788	924	954	852
Rhode Island	85	75	72	53	68	68	49
South Carolina	701	726	721	655	648	717	758
South Dakota	41	29	34	37	31	40	51
Tennessee	718	740	767	647	830	860	778
Texas	4,361	4,421	4,370	3,616	4,510	4,896	4,400
Utah	116	123	137	132	134	155	167
Vermont	21	18	11	13	12	4	9
Virginia	863	859	833	620	793	834	797
Washington	436	497	478	416	460	491	428
West Virginia	79	92	153	139	150	136	94
Wisconsin	258	208	209	213	252	291	226
Wyoming	10	12	13	14	7	13	21
<b>Subtotal</b>	<b>38,048</b>	<b>37,132</b>	<b>36,350</b>	<b>30,317</b>	<b>35,671</b>	<b>37,601</b>	<b>34,207</b>
<b>U.S. territories and freely associated states</b>							
American Samoa	0	0	0	0	0	0	0
Guam	5	7	11	1	0	0	0
Northern Mariana Islands	1	1	2	0	0	0	0
Puerto Rico	448	438	391	305	415	365	360
Republic of Palau	0	0	0	0	0	0	0
U.S. Virgin Islands	10	16	14	7	10	15	5
<b>Subtotal</b>	<b>464</b>	<b>462</b>	<b>418</b>	<b>313</b>	<b>425</b>	<b>380</b>	<b>365</b>
<b>Total</b>	<b>38,512</b>	<b>37,594</b>	<b>36,768</b>	<b>30,630</b>	<b>36,096</b>	<b>37,981</b>	<b>34,572</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau. Data are based on residence at HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through December 2023.

<sup>a</sup> Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. Therefore, readers should also consider the potential influence of COVID-19 on HIV data for subsequent years.

<sup>b</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 3d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017–2023—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) <sup>a</sup> No.	2021 No.	2022 No.	2023 (preliminary) <sup>b</sup> No.
<b>Arizona</b>							
Maricopa County	488	528	501	465	510	579	545
<b>California</b>							
Alameda County	202	203	219	162	188	206	176
Los Angeles County	1,782	1,736	1,590	1,437	1,526	1,600	1,333
Orange County	314	287	245	265	267	257	245
Riverside County	275	263	268	237	272	320	248
Sacramento County	183	180	166	158	184	194	122
San Bernardino County	256	263	298	265	299	288	225
San Diego County	420	390	407	330	391	402	326
San Francisco County	242	237	210	157	191	214	169
<b>District of Columbia</b>	310	277	255	196	198	211	207
<b>Florida</b>							
Broward County	623	549	523	410	537	579	599
Duval County	288	265	278	224	271	280	265
Hillsborough County	289	276	245	231	279	287	366
Miami-Dade County	1,050	1,058	1,019	716	865	1,021	1,010
Orange County	446	416	431	352	389	417	463
Palm Beach County	274	257	213	195	271	285	255
Pinellas County	157	173	176	154	117	112	149
<b>Georgia</b>							
Cobb County	157	155	177	140	145	171	145
DeKalb County	368	357	344	263	333	361	277
Fulton County	616	594	533	467	513	509	421
Gwinnett County	180	148	215	147	159	209	194
<b>Illinois</b>							
Cook County	997	983	913	764	833	868	769
<b>Indiana</b>							
Marion County	226	206	201	169	222	251	240
<b>Louisiana</b>							
East Baton Rouge Parish	163	177	156	122	141	131	128
Orleans Parish	176	175	159	101	144	125	135
<b>Maryland</b>							
Baltimore City	235	230	193	174	155	160	152
Montgomery County	161	126	131	78	94	105	91
Prince George's County	301	305	282	221	221	254	180
<b>Massachusetts</b>							
Suffolk County	163	146	133	131	128	115	88
<b>Michigan</b>							
Wayne County	323	300	289	228	255	248	281
<b>Nevada</b>							
Clark County	449	442	450	343	446	483	459
<b>New Jersey</b>							
Essex County	306	258	224	193	233	229	173
Hudson County	155	158	148	113	133	165	98
<b>New York</b>							
Bronx County	499	463	507	351	419	397	343
Kings County	639	552	480	450	450	491	399
New York County	401	374	346	296	320	332	265
Queens County	432	421	360	325	325	357	379

**Table 3d. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, 2017–2023—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	2017 No.	2018 No.	2019 No.	2020 (COVID-19 pandemic) <sup>a</sup> No.	2021 No.	2022 No.	2023 (preliminary) <sup>b</sup> No.
<b>North Carolina</b>							
Mecklenburg County	270	238	265	209	278	276	258
<b>Ohio</b>							
Cuyahoga County	148	150	159	183	166	118	139
Franklin County	223	194	216	206	191	192	173
Hamilton County	187	183	172	131	122	93	67
<b>Pennsylvania</b>							
Philadelphia County	513	440	443	336	369	385	339
<b>Puerto Rico</b>							
San Juan Municipio	113	104	87	79	98	108	86
<b>Tennessee</b>							
Shelby County	258	290	261	235	292	338	270
<b>Texas</b>							
Bexar County	346	322	335	285	331	357	278
Dallas County	820	792	758	665	791	896	740
Harris County	1,104	1,210	1,228	948	1,182	1,260	1,185
Tarrant County	303	281	322	297	309	329	295
Travis County	213	189	182	163	229	236	202
<b>Washington</b>							
King County	213	288	241	198	215	250	186

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through December 2023.

<sup>a</sup> Data for 2020, which coincided with the onset of the COVID-19 pandemic, should be interpreted with caution. The pandemic had a significant impact on access to HIV testing, care, and related services, and case surveillance activities in state and local jurisdictions. Therefore, readers should also consider the potential influence of COVID-19 on HIV data for subsequent years.

<sup>b</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.



**Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2022 through September 2023—48 states and the District of Columbia**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2022</b>					
<b>Gender</b>					
Man	28,785	23,563	81.9	5,222	18.1
Woman	6,710	5,373	80.1	1,337	19.9
Transgender woman <sup>a</sup>	851	700	82.3	151	17.7
Transgender man <sup>a</sup>	59	53	89.8	6	10.2
Additional gender identity <sup>b</sup>	65	64	98.5	1	1.5
<b>Age at diagnosis (yr)</b>					
13–24	6,884	5,530	80.3	1,354	19.7
25–34	13,572	11,052	81.4	2,520	18.6
35–44	8,017	6,578	82.1	1,439	17.9
45–54	4,400	3,618	82.2	782	17.8
55–64	2,753	2,282	82.9	471	17.1
≥65	844	693	82.1	151	17.9
<b>Race/ethnicity</b>					
American Indian/Alaska Native	213	166	77.9	47	22.1
Asian	773	681	88.1	92	11.9
Black/African American	14,198	11,117	78.3	3,081	21.7
Hispanic/Latino <sup>c</sup>	11,270	9,576	85.0	1,694	15.0
Native Hawaiian/other Pacific Islander	83	61	73.5	22	26.5
White	8,924	7,326	82.1	1,598	17.9
Multiracial	1,009	826	81.9	183	18.1
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact <sup>e</sup>	24,490	20,212	82.5	4,278	17.5
Injection drug use <sup>f</sup>	2,532	1,925	76.0	607	24.0
Male	1,408	1,060	75.3	348	24.7
Female	1,124	864	76.9	259	23.1
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	1,298	1,047	80.7	251	19.3
Heterosexual contact <sup>g</sup>	8,073	6,506	80.6	1,567	19.4
Male	2,468	1,977	80.1	491	19.9
Female	5,605	4,529	80.8	1,076	19.2
<b>Total<sup>h</sup></b>	<b>36,470</b>	<b>29,753</b>	<b>81.6</b>	<b>6,717</b>	<b>18.4</b>

**Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2022 through September 2023—48 states and the District of Columbia (cont)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2023 (January–September, preliminary)<sup>i</sup></b>					
<b>Gender</b>					
Man	21,961	18,199	82.9	3,762	17.1
Woman	5,303	4,319	81.4	984	18.6
Transgender woman <sup>a</sup>	523	468	89.5	55	10.5
Transgender man <sup>a</sup>	45	42	93.3	3	6.7
Additional gender identity <sup>b</sup>	67	60	89.6	7	10.4
<b>Age at diagnosis (yr)</b>					
13–24	5,006	4,091	81.7	915	18.3
25–34	10,323	8,565	83.0	1,758	17.0
35–44	6,380	5,270	82.6	1,110	17.4
45–54	3,400	2,844	83.6	556	16.4
55–64	2,085	1,732	83.1	353	16.9
≥65	707	587	83.0	120	17.0
<b>Race/ethnicity</b>					
American Indian/Alaska Native	142	114	80.3	28	19.7
Asian	580	491	84.7	89	15.3
Black/African American	10,992	8,743	79.5	2,249	20.5
Hispanic/Latino <sup>c</sup>	8,697	7,472	85.9	1,225	14.1
Native Hawaiian/other Pacific Islander	45	39	86.7	6	13.3
White	6,820	5,706	83.7	1,114	16.3
Multiracial	625	524	83.8	101	16.2
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact <sup>e</sup>	18,646	15,600	83.7	3,046	16.3
Injection drug use <sup>f</sup>	1,753	1,383	78.9	370	21.1
Male	979	761	77.7	218	22.3
Female	774	622	80.4	152	19.6
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	901	726	80.6	175	19.4
Heterosexual contact <sup>g</sup>	6,539	5,329	81.5	1,210	18.5
Male	1,996	1,617	81.0	379	19.0
Female	4,543	3,712	81.7	831	18.3
<b>Total<sup>h</sup></b>	<b>27,901</b>	<b>23,089</b>	<b>82.8</b>	<b>4,812</b>	<b>17.2</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>a</sup> “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

<sup>b</sup> Additional gender identity includes “nonbinary,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

<sup>e</sup> Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>f</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>g</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>h</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

<sup>i</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 4b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through September 2023—48 states and the District of Columbia**

Area of residence	2022					2023 (January–September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Alabama	701	552	78.7	149	21.3	410	104	25.4	306	74.6
Alaska	38	34	89.5	4	10.5	21	17	81.0	4	19.0
Arizona	860	722	84.0	138	16.0	761	641	84.2	120	15.8
Arkansas	305	247	81.0	58	19.0	262	230	87.8	32	12.2
California	4,856	3,986	82.1	870	17.9	3,432	2,963	86.3	469	13.7
Colorado	433	365	84.3	68	15.7	362	300	82.9	62	17.1
Connecticut	220	186	84.5	34	15.5	165	137	83.0	28	17.0
Delaware	128	105	82.0	23	18.0	80	66	82.5	14	17.5
District of Columbia	211	182	86.3	29	13.7	168	135	80.4	33	19.6
Florida	4,290	3,552	82.8	738	17.2	3,643	3,000	82.3	643	17.7
Georgia	2,511	2,014	80.2	497	19.8	1,708	1,451	85.0	257	15.0
Hawaii	78	66	84.6	12	15.4	40	34	85.0	6	15.0
Illinois	1,306	1,087	83.2	219	16.8	962	816	84.8	146	15.2
Indiana	612	472	77.1	140	22.9	512	396	77.3	116	22.7
Iowa	123	113	91.9	10	8.1	109	102	93.6	7	6.4
Kansas	133	119	89.5	14	10.5	125	100	80.0	25	20.0
Kentucky	405	319	78.8	86	21.2	303	250	82.5	53	17.5
Louisiana	856	676	79.0	180	21.0	677	562	83.0	115	17.0
Maine	41	38	92.7	3	7.3	26	25	96.2	1	3.8
Maryland	748	638	85.3	110	14.7	533	483	90.6	50	9.4
Massachusetts	438	387	88.4	51	11.6	304	276	90.8	28	9.2
Michigan	629	541	86.0	88	14.0	530	432	81.5	98	18.5
Minnesota	261	224	85.8	37	14.2	244	223	91.4	21	8.6
Mississippi <sup>b</sup>	448	235	52.5	213	47.5	340	269	79.1	71	20.9
Missouri	512	415	81.1	97	18.9	431	363	84.2	68	15.8
Montana	11	8	72.7	3	27.3	18	17	94.4	1	5.6
Nebraska	91	78	85.7	13	14.3	79	68	86.1	11	13.9
Nevada	528	467	88.4	61	11.6	422	354	83.9	68	16.1
New Hampshire	28	20	71.4	8	28.6	21	17	81.0	4	19.0
New Mexico	94	83	88.3	11	11.7	23	16	69.6	7	30.4
New York	2,226	1,923	86.4	303	13.6	1,714	1,481	86.4	233	13.6
North Carolina	1,353	1,084	80.1	269	19.9	1,069	858	80.3	211	19.7
North Dakota	38	34	89.5	4	10.5	15	12	80.0	3	20.0
Ohio	855	699	81.8	156	18.2	639	528	82.6	111	17.4
Oklahoma	394	318	80.7	76	19.3	197	172	87.3	25	12.7
Oregon	250	206	82.4	44	17.6	165	151	91.5	14	8.5
Pennsylvania	954	788	82.6	166	17.4	700	599	85.6	101	14.4
Rhode Island	68	62	91.2	6	8.8	39	36	92.3	3	7.7
South Carolina	717	560	78.1	157	21.9	712	632	88.8	80	11.2
South Dakota	40	28	70.0	12	30.0	44	39	88.6	5	11.4
Tennessee	860	601	69.9	259	30.1	678	468	69.0	210	31.0
Texas	4,896	3,913	79.9	983	20.1	3,811	3,093	81.2	718	18.8
Utah	155	125	80.6	30	19.4	128	103	80.5	25	19.5
Vermont	4	4	100	0	0.0	7	6	85.7	1	14.3
Virginia	834	684	82.0	150	18.0	676	563	83.3	113	16.7
Washington	491	433	88.2	58	11.8	323	273	84.5	50	15.5
West Virginia <sup>b</sup>	136	85	62.5	51	37.5	75	48	64.0	27	36.0
Wisconsin	291	263	90.4	28	9.6	182	166	91.2	16	8.8
Wyoming	13	12	92.3	1	7.7	16	14	87.5	2	12.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>a</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>b</sup> Data should be interpreted with caution due to a lapse in laboratory data completeness that occurred during the year 2022.

**Table 4c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
		<b>2022</b>			
<b>Arizona</b>					
Maricopa County	579	487	84.1	92	15.9
<b>California</b>					
Alameda County	206	180	87.4	26	12.6
Los Angeles County	1,600	1,283	80.2	317	19.8
Orange County	257	219	85.2	38	14.8
Riverside County	320	255	79.7	65	20.3
Sacramento County	194	162	83.5	32	16.5
San Bernardino County	288	204	70.8	84	29.2
San Diego County	402	334	83.1	68	16.9
San Francisco County	214	193	90.2	21	9.8
<b>District of Columbia</b>	211	182	86.3	29	13.7
<b>Florida</b>					
Broward County	579	468	80.8	111	19.2
Duval County	280	203	72.5	77	27.5
Hillsborough County	287	240	83.6	47	16.4
Miami-Dade County	1,021	848	83.1	173	16.9
Orange County	417	338	81.1	79	18.9
Palm Beach County	285	248	87.0	37	13.0
Pinellas County	112	97	86.6	15	13.4
<b>Georgia</b>					
Cobb County	171	142	83.0	29	17.0
DeKalb County	361	294	81.4	67	18.6
Fulton County	509	409	80.4	100	19.6
Gwinnett County	209	173	82.8	36	17.2
<b>Illinois</b>					
Cook County	868	725	83.5	143	16.5
<b>Indiana</b>					
Marion County	251	199	79.3	52	20.7
<b>Louisiana</b>					
East Baton Rouge Parish	131	114	87.0	17	13.0
Orleans Parish	125	102	81.6	23	18.4
<b>Maryland</b>					
Baltimore City	160	137	85.6	23	14.4
Montgomery County	105	91	86.7	14	13.3
Prince George's County	254	220	86.6	34	13.4
<b>Massachusetts</b>					
Suffolk County	115	103	89.6	12	10.4
<b>Michigan</b>					
Wayne County	248	206	83.1	42	16.9
<b>Nevada</b>					
Clark County	483	427	88.4	56	11.6
<b>New York</b>					
Bronx County	397	335	84.4	62	15.6
Kings County	491	436	88.8	55	11.2
New York County	332	269	81.0	63	19.0
Queens County	357	321	89.9	36	10.1

**Table 4c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2022 (cont)</b>					
<b>North Carolina</b>					
Mecklenburg County	276	221	80.1	55	19.9
<b>Ohio</b>					
Cuyahoga County	118	99	83.9	19	16.1
Franklin County	192	161	83.9	31	16.1
Hamilton County	93	79	84.9	14	15.1
<b>Pennsylvania</b>					
Philadelphia County	385	307	79.7	78	20.3
<b>Tennessee</b>					
Shelby County	338	218	64.5	120	35.5
<b>Texas</b>					
Bexar County	357	285	79.8	72	20.2
Dallas County	896	688	76.8	208	23.2
Harris County	1,260	992	78.7	268	21.3
Tarrant County	329	263	79.9	66	20.1
Travis County	236	208	88.1	28	11.9
<b>Washington</b>					
King County	250	227	90.8	23	9.2
<b>2023 (January–September, preliminary)<sup>a</sup></b>					
<b>Arizona</b>					
Maricopa County	510	434	85.1	76	14.9
<b>California</b>					
Alameda County	150	133	88.7	17	11.3
Los Angeles County	1,134	974	85.9	160	14.1
Orange County	194	176	90.7	18	9.3
Riverside County	209	181	86.6	28	13.4
Sacramento County	119	105	88.2	14	11.8
San Bernardino County	197	144	73.1	53	26.9
San Diego County	284	252	88.7	32	11.3
San Francisco County	144	137	95.1	7	4.9
<b>District of Columbia</b>					
	168	135	80.4	33	19.6
<b>Florida</b>					
Broward County	477	378	79.2	99	20.8
Duval County	223	175	78.5	48	21.5
Hillsborough County	285	241	84.6	44	15.4
Miami-Dade County	843	681	80.8	162	19.2
Orange County	372	315	84.7	57	15.3
Palm Beach County	197	164	83.2	33	16.8
Pinellas County	121	94	77.7	27	22.3
<b>Georgia</b>					
Cobb County	125	108	86.4	17	13.6
DeKalb County	222	195	87.8	27	12.2
Fulton County	337	292	86.6	45	13.4
Gwinnett County	147	134	91.2	13	8.8
<b>Illinois</b>					
Cook County	653	554	84.8	99	15.2

**Table 4c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2023 (January–September, preliminary)<sup>a</sup> (cont)</b>				
<b>Indiana</b>					
Marion County	212	178	84.0	34	16.0
<b>Louisiana</b>					
East Baton Rouge Parish	102	81	79.4	21	20.6
Orleans Parish	92	76	82.6	16	17.4
<b>Maryland</b>					
Baltimore City	120	111	92.5	9	7.5
Montgomery County	75	65	86.7	10	13.3
Prince George's County	153	139	90.8	14	9.2
<b>Massachusetts</b>					
Suffolk County	86	80	93.0	6	7.0
<b>Michigan</b>					
Wayne County	219	169	77.2	50	22.8
<b>Nevada</b>					
Clark County	373	313	83.9	60	16.1
<b>New York</b>					
Bronx County	280	237	84.6	43	15.4
Kings County	333	271	81.4	62	18.6
New York County	233	195	83.7	38	16.3
Queens County	317	286	90.2	31	9.8
<b>North Carolina</b>					
Mecklenburg County	211	179	84.8	32	15.2
<b>Ohio</b>					
Cuyahoga County	117	104	88.9	13	11.1
Franklin County	157	134	85.4	23	14.6
Hamilton County	65	58	89.2	7	10.8
<b>Pennsylvania</b>					
Philadelphia County	288	252	87.5	36	12.5
<b>Tennessee</b>					
Shelby County	239	146	61.1	93	38.9
<b>Texas</b>					
Bexar County	245	199	81.2	46	18.8
Dallas County	629	493	78.4	136	21.6
Harris County	1,032	838	81.2	194	18.8
Tarrant County	271	223	82.3	48	17.7
Travis County	166	156	94.0	10	6.0
<b>Washington</b>					
King County	136	117	86.0	19	14.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>a</sup> Data for the year 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 5a. HIV viral suppression during 2022 among persons aged ≥13 years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by selected characteristics—48 states and the District of Columbia**

	Persons alive at year-end 2022		VL <200 copies/mL	
	Total No.	No.	%	
<b>Gender</b>				
Man	774,351	507,654	65.6	
Woman	229,653	145,789	63.5	
Transgender woman <sup>a</sup>	13,440	8,947	66.6	
Transgender man <sup>a</sup>	589	434	73.7	
Additional gender identity <sup>b</sup>	395	296	74.9	
<b>Age at year-end 2021 (yr)</b>				
13–24	27,725	18,196	65.6	
25–34	159,748	100,810	63.1	
35–44	195,969	124,316	63.4	
45–54	231,600	150,956	65.2	
55–64	271,343	184,750	68.1	
≥65	132,045	84,093	63.7	
<b>Race/ethnicity</b>				
American Indian/Alaska Native	3,032	1,970	65.0	
Asian <sup>c</sup>	16,060	11,142	69.4	
Black/African American	406,193	245,790	60.5	
Hispanic/Latino <sup>d</sup>	245,667	157,878	64.3	
Native Hawaiian/other Pacific Islander	885	565	63.8	
White	290,961	206,015	70.8	
Multiracial	55,030	39,722	72.2	
<b>Transmission category<sup>e</sup></b>				
Male-to-male sexual contact <sup>f</sup>	593,383	403,049	67.9	
Injection drug use <sup>g</sup>	101,292	55,552	54.8	
Male	57,791	29,626	51.3	
Female	43,501	25,926	59.6	
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	55,066	35,717	64.9	
Heterosexual contact <sup>h</sup>	253,800	160,335	63.2	
Male	74,417	44,342	59.6	
Female	179,383	115,993	64.7	
Other <sup>i</sup>	14,889	8,469	56.9	
Male	7,487	4,132	55.2	
Female	7,402	4,337	58.6	
<b>Total<sup>j</sup></b>	<b>1,018,430</b>	<b>663,121</b>	<b>65.1</b>	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2022 (i.e., most recent known address). Data for the year 2022 are preliminary and based on death data received by CDC as of December 2023. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>a</sup> “Transgender woman” includes persons who were assigned male sex at birth but have ever identified as a woman. “Transgender man” includes persons who were assigned female sex at birth but have ever identified as a man.

<sup>b</sup> Additional gender identity includes “nonbinary,” “gender queer,” and “two-spirit.”

<sup>c</sup> Includes Asian/Pacific Islander legacy cases.

<sup>d</sup> Hispanic/Latino persons can be of any race.

<sup>e</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of reported data by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

<sup>f</sup> Includes persons assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and persons assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>g</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>h</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>i</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>j</sup> Includes 2 persons of unknown gender and 602 persons of unknown race/ethnicity.

**Table 5b. HIV viral suppression during 2022 among persons aged ≥13 years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by area of residence—48 states and the District of Columbia**

Area of residence	Persons alive at year-end 2022		VL <200 copies/mL	
	Total No.	No.	%	
Alabama	14,066	7,616	54.1	
Alaska	727	552	75.9	
Arizona	17,879	10,624	59.4	
Arkansas	6,055	3,810	62.9	
California	133,712	89,165	66.7	
Colorado	13,285	7,375	55.5	
Connecticut	10,413	5,607	53.8	
Delaware	3,512	2,631	74.9	
District of Columbia	13,338	7,680	57.6	
Florida	116,142	80,497	69.3	
Georgia	58,476	36,850	63.0	
Hawaii	2,357	1,837	77.9	
Illinois	34,920	21,638	62.0	
Indiana	12,169	8,484	69.7	
Iowa	3,094	2,513	81.2	
Kansas	3,480	2,546	73.2	
Kentucky	8,057	5,936	73.7	
Louisiana	20,983	14,725	70.2	
Maine	1,711	1,338	78.2	
Maryland	32,811	19,764	60.2	
Massachusetts	20,871	14,076	67.4	
Michigan	16,947	12,196	72.0	
Minnesota	9,192	6,304	68.6	
Mississippi <sup>a,b</sup>	9,488	3,188	33.6	
Missouri	12,761	8,303	65.1	
Montana	710	562	79.2	
Nebraska	2,327	1,611	69.2	
Nevada	11,236	7,170	63.8	
New Hampshire	1,358	964	71.0	
New Mexico	3,897	2,668	68.5	
New York	122,512	79,733	65.1	
North Carolina	33,673	21,924	65.1	
North Dakota	508	223	43.9	
Ohio	23,648	15,970	67.5	
Oklahoma	6,889	4,383	63.6	
Oregon	7,313	5,735	78.4	
Pennsylvania	36,094	22,762	63.1	
Rhode Island	2,678	1,961	73.2	
South Carolina <sup>b</sup>	17,754	11,398	64.2	
South Dakota	726	458	63.1	
Tennessee	18,501	12,648	68.4	
Texas	100,285	61,697	61.5	
Utah <sup>b</sup>	3,468	2,401	69.2	
Vermont	750	555	74.0	
Virginia	24,051	15,462	64.3	
Washington	14,426	11,297	78.3	
West Virginia <sup>a</sup>	2,162	905	41.9	
Wisconsin	6,653	5,126	77.0	
Wyoming	365	253	69.3	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on address of residence as of December 31, 2022 (i.e., most recent known address). Data for the year 2022 are preliminary and based on death data received by CDC as of December 2023. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

<sup>a</sup> Data should be interpreted with caution due to a lapse in laboratory data completeness that occurred during the year 2022.

<sup>b</sup> Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2022.



**Table 5c. HIV viral suppression during 2022 among persons aged ≥13 years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by area of residence—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	Persons alive at year-end 2022 Total No.	VL <200 copies/mL	
		No.	%
<b>Arizona</b>			
Maricopa County	12,136	7,117	58.6
<b>California</b>			
Alameda County	5,785	4,156	71.8
Los Angeles County	49,421	32,168	65.1
Orange County	7,077	4,634	65.5
Riverside County	10,265	8,014	78.1
Sacramento County	4,490	3,190	71.0
San Bernardino County	4,967	2,976	59.9
San Diego County	13,363	7,980	59.7
San Francisco County	11,346	8,506	75.0
<b>District of Columbia</b>	13,338	7,680	57.6
<b>Florida</b>			
Broward County	20,154	14,500	71.9
Duval County	6,343	4,258	67.1
Hillsborough County	7,368	5,398	73.3
Miami-Dade County	26,949	16,502	61.2
Orange County	9,197	6,597	71.7
Palm Beach County	8,111	5,383	66.4
Pinellas County	4,842	3,783	78.1
<b>Georgia</b>			
Cobb County	3,612	2,410	66.7
DeKalb County	8,844	5,738	64.9
Fulton County	15,887	10,116	63.7
Gwinnett County	3,348	2,278	68.0
<b>Illinois</b>			
Cook County	25,127	14,891	59.3
<b>Indiana</b>			
Marion County	4,870	3,328	68.3
<b>Louisiana</b>			
East Baton Rouge Parish	3,868	2,949	76.2
Orleans Parish	4,677	3,270	69.9
<b>Maryland</b>			
Baltimore City	10,104	6,222	61.6
Montgomery County	3,941	2,010	51.0
Prince George's County	7,945	4,558	57.4
<b>Massachusetts</b>			
Suffolk County	5,506	3,590	65.2
<b>Michigan</b>			
Wayne County	6,996	4,731	67.6
<b>Nevada</b>			
Clark County	9,581	6,150	64.2
<b>New York</b>			
Bronx County	26,702	17,782	66.6
Kings County	25,553	15,992	62.6
New York County	25,598	15,673	61.2
Queens County	16,087	10,249	63.7

**Table 5c. HIV viral suppression during 2022 among persons aged  $\geq 13$  years with HIV diagnosed by year-end 2021 and alive at year-end 2022, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (cont)**

Area of residence	Persons alive at year-end 2022 Total No.	VL <200 copies/mL	
		No.	%
<b>North Carolina</b>			
Mecklenburg County	6,398	4,394	68.7
<b>Ohio</b>			
Cuyahoga County	4,860	3,240	66.7
Franklin County	5,163	3,607	69.9
Hamilton County	3,075	1,963	63.8
<b>Pennsylvania</b>			
Philadelphia County	16,401	10,214	62.3
<b>Tennessee</b>			
Shelby County	6,463	4,181	64.7
<b>Texas</b>			
Bexar County	6,776	4,536	66.9
Dallas County	19,302	11,700	60.6
Harris County	27,605	16,137	58.5
Tarrant County	6,384	4,045	63.4
Travis County	5,170	3,672	71.0
<b>Washington</b>			
King County	7,032	5,660	80.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm<sup>3</sup> or cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on address of residence as of December 31, 2022 (i.e., most recent known address). Data for the year 2022 are preliminary and based on death data received by CDC as of December 2023. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey and Puerto Rico.

**Table 6. Ending the HIV Epidemic Phase I jurisdictions**

<b>Counties</b>	<b>Territories</b>	<b>States</b>
<b>Arizona</b>	<b>Puerto Rico<sup>a</sup></b>	Alabama
Maricopa County	San Juan Municipio <sup>a</sup>	Arkansas
<b>California</b>		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
<b>District of Columbia</b>		
<b>Florida</b>		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
<b>Georgia</b>		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
<b>Illinois</b>		
Cook County		
<b>Indiana</b>		
Marion County		
<b>Louisiana</b>		
East Baton Rouge Parish		
Orleans Parish		
<b>Maryland</b>		
Baltimore City		
Montgomery County		
Prince George's County		
<b>Massachusetts</b>		
Suffolk County		
<b>Michigan</b>		
Wayne County		
<b>Nevada</b>		
Clark County		
<b>New Jersey<sup>a</sup></b>		
Essex County <sup>a</sup>		
Hudson County <sup>a</sup>		
<b>New York</b>		
Bronx County		
Kings County		
New York County		
Queens County		

**Table 6. Ending the HIV Epidemic Phase I jurisdictions (cont)**

Counties	Territories	States
<b>North Carolina</b>		
Mecklenburg County		
<b>Ohio</b>		
Cuyahoga County		
Franklin County		
Hamilton County		
<b>Pennsylvania</b>		
Philadelphia County		
<b>Tennessee</b>		
Shelby County		
<b>Texas</b>		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
<b>Washington</b>		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

<sup>a</sup> Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey and Puerto Rico.

**Table 7. Monitoring Ending the HIV Epidemic indicators by using data from the National HIV Surveillance System (NHSS) and other reporting systems**

	2017 <sup>a</sup>	2018	2019	2020 (COVID-19 pandemic)	2021	2022
Reduce the estimated number of new HIV infections by 90%	37,000	36,200	35,100	34,200	32,700	31,800
Increase the percentage of people living with HIV who know their serostatus to at least 95% (knowledge of HIV status)	85.8	85.9	86.3	86.5	86.8	87.2
Reduce the number of new HIV diagnoses by 90%	38,531	37,132	36,350	30,317	35,671	37,601
Increase the percentage of persons with newly diagnosed HIV infection linked to HIV medical care within one month of diagnosis to at least 95%	77.8	80.2	81.3	82.4	81.9	81.6
Increase the percentage of persons with diagnosed HIV infection who are virally suppressed to at least 95%	63.1	64.7	65.5	64.6	65.9	65.1
Increase the percentage of the estimated number of persons with indications for PrEP who have been classified as having been prescribed PrEP to at least 50% (PrEP coverage) <sup>b</sup>	13.2	18.2	22.7	24.8	30.2	36.0

Abbreviation: PrEP, preexposure prophylaxis.

*Note.* Information on the Ending the HIV Epidemic in the U.S. initiative is available at <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. All data presented are for persons aged ≥13 years, except PrEP coverage which is for persons aged ≥16 years.

<sup>a</sup> Baseline data for EHE indicators published at <https://stacks.cdc.gov/view/cdc/149183>. Baseline data for PrEP EHE indicator published at <https://stacks.cdc.gov/view/cdc/149192>.

<sup>b</sup> PrEP coverage, reported as a percentage, for persons aged ≥16 years was calculated as the number of persons classified as having been prescribed PrEP divided by the estimated number of persons who had indications for PrEP. CDC advises readers not to cite the previously published estimates, as they are subject to change.